The headline sounds like something from a tech magazine circa 2040. “Control games with your mind.” And yet it’s May 2026, and you genuinely can do this. A pair of headphones with EEG sensors in the ear pads ships to your door for $499. A 19-year-old in Shanghai with a brain implant cleared the opening stages of Black Myth: Wukong using only his thoughts. Noland Arbaugh, who hasn’t been able to move his hands since a diving accident eight years ago, played Mario Kart with his father.

All of that is real. All of it happened recently. And if you’re excited by those three sentences, you should probably read a little further before you reach for your credit card — because “controlling a game with your mind” means something completely different depending on which technology you’re talking about, and most of the consumer-facing version is a lot more modest than the marketing implies. That’s not a reason to dismiss it. But it is a reason to understand what you’re actually buying.

What the consumer version actually does 🧠

Let’s start where most people will start: the devices you can actually buy without a surgeon. The most sophisticated consumer mind-control gaming product available right now is probably the Neurable MW75 Neuro, a collaboration between Neurable AI and Master & Dynamic. The original model costs $699. The newer MW75 Neuro LT, released in September 2025, trimmed about 12% of the weight and dropped to $499 — still not impulse-buy territory, but more realistic than the flagship.

These headphones look nearly identical to standard premium wireless headphones. The difference is in the ear pads: they contain 12 EEG channels made from soft fabric sensors that measure your brain’s electrical activity in real time. Neurable’s AI processes those signals and generates metrics — Focus Level, Calmness, Cognitive Speed, Anxiety Score — updated every second. The SoundGuys review describes the experience of seeing your focus spike as you concentrate on a task and flatten as your mind wanders. One reviewer wore the headset while playing a side-scrolling shooter on a Steam Deck and watched the data trace their learning curve in the first level, then settle as the controls became automatic.

This is real. It’s not pseudoscience, and it’s not fake. Neurable validated the technology in a study with 132 participants, and they’ve done follow-on work with the Mayo Clinic. The headset really does capture meaningful neural signals from an otherwise normal-looking pair of headphones.

Here’s the catch: what it does with those signals is not direct game control. Not yet. The MW75 Neuro tracks your cognitive state — how focused you are, when you’re approaching mental fatigue — and uses that data to suggest brain breaks, show you productivity patterns, and give you a window into how your brain performs through the day. The gaming application is more about self-awareness than mind control. You wear the headset while gaming and see the neural data alongside your session. You don’t move characters with your thoughts.

What consumer EEG gaming actually looks like in 2026:

• Passive cognitive monitoring during gameplay — tracking attention states, alertness, and focus as overlays or companion app data

• Simple binary control in purpose-built applications — games designed specifically for BCI input, where you “push” with concentration or “pull” with relaxation, a bit like pressing a single button with your brain

• Adaptive game environments that adjust difficulty based on your measured mental load — easier when you’re fatigued, harder when you’re locked in

• Neurofeedback games where the explicit goal is to practice brain control, training attention regulation rather than playing traditional games

That’s meaningful. That’s actually a category of experience that didn’t exist five years ago. But if you’re imagining yourself steering a car through a Mario Kart track purely by thinking “left” and “right,” you’re picturing something the consumer hardware can’t deliver today. 💡

What the implant version actually feels like ⚡

For the full version — the one where you’re playing a complex video game with your thoughts at something approaching normal speed and accuracy — you need an implant. That’s the honest answer, and I think it’s important to say it plainly rather than let the consumer marketing blur the line.

Noland Arbaugh became the first person to receive Neuralink’s “Telepathy” N1 chip in January 2024. The device sits in his skull, sealed, with ultra-thin electrode threads woven into his motor cortex. Within a month, he was controlling a cursor on his laptop screen by imagining moving a cursor. Then came chess. Then Mario Kart with his father watching. As Arbaugh told Neuralink’s company meeting: “I am so blessed to be part of it. It’s only been a month and I can’t believe how much my life has changed.”

Arbaugh described the experience as imagining moving his hand, even though his hand doesn’t move. The signal that would have driven hand movement is intercepted by the chip before it reaches his paralyzed muscles, decoded by software, and translated into cursor position on screen. It’s not reading thoughts exactly — it’s reading motor intent. The distinction matters, because it means the training process is largely about learning to produce consistent motor imagery, which most people can do once they understand what the system is looking for.

In April 2025, a different story emerged from Shanghai. BrainXBot — a collaboration involving the Tianqiao Brain Science Research Institute and the Shanghai Institute of Microsystems — reported that a 19-year-old epilepsy patient played complex games after receiving their Beinao-1 implant. According to Tom’s Hardware’s reporting, the training process took roughly 20 hours — about three times faster than Arbaugh’s initial Neuralink training — and the patient achieved 4.07 bits per second of cursor control performance, approaching the 4.6 bits per second Arbaugh achieved after 60 hours. He played Black Myth: Wukong and Honor of Kings and also controlled a smart wheelchair and home devices using the same system.

The patient’s pathway to gaming:

• Started with basic titles like Pac-Man and Tank Wars to build motor imagery consistency

• Graduated to cursor-based internet navigation, app control, and smart home commands

• Reached complex action games after approximately 20 hours of brain training

• Achieved cursor response speed “approaching the level of normal people using a mouse,” according to the company

The physical sensation of using an implanted BCI is something no reviewer has described in the way you’d describe holding a controller. Arbaugh said it felt natural quickly — that imagining movement became an almost unconscious process after a while, the way you stop thinking about which fingers press which keys when you type. That’s the version of mind-controlled gaming that feels like the science fiction. It’s also the version that currently requires open-skull surgery. 🔬

The gap — and why it’s not as simple as “wait for better technology” 📈

Consumer EEG and implanted BCI aren’t really on the same innovation timeline heading toward the same destination. They’re different tools for different things, and understanding that is more useful than assuming one will eventually become the other.

The limitations of non-invasive EEG for high-fidelity game control are physics problems, not just engineering problems. Your skull scatters electrical signals badly. The sensor sits centimeters from the neurons generating the signal, separated by bone, fluid, and tissue. The result is blurry, low-resolution data compared to what you get from an electrode touching the cortex directly. A 2024 study flagged what researchers call “BCI illiteracy“ — the finding that roughly 20% of potential users simply cannot generate the kind of consistent, distinguishable brain signals that consumer EEG needs to decode intent reliably. That’s not a fixable user error. For some people’s neural architecture, EEG control of complex inputs may never work well.

That’s a specific limitation worth naming. A technology that doesn’t work for one in five people isn’t ready to be everyone’s controller. The honest framing from neuroscientists is that consumer EEG gaming today is best thought of as a layer of information on top of traditional input rather than a replacement for it. You play the game normally; the EEG data enriches the experience or adapts the environment.

Implanted BCIs face a different set of constraints:

• Surgical requirement limits the addressable population to people for whom the medical benefit clearly outweighs the risk

• Regulatory pathways mean every new application (gaming, communication, vision, emotion) needs its own clinical evidence

• Device longevity is still being established — how long do these implants remain functional and safe? Years of data are still being collected

• Electrode drift can degrade signal quality over time as tissue gradually reacts to the implant

I find the discourse around this frustrating because it tends to collapse into either “mind control gaming is almost here” hype or “this is dangerous sci-fi” dismissal, when the actual picture is more nuanced. The technology is real and working, it helps real people meaningfully, and the path to mainstream gaming applications involves solving problems that range from practical engineering to regulatory philosophy. That’s worth sitting with rather than skipping past. 💡

Where the hardware is actually heading 🚀

The most instructive recent data point isn’t from Neuralink or BrainXBot. It’s a January 2025 paper in Nature Medicine from a Stanford University team led by researchers working with a participant who has tetraplegia. They developed a finger-based BCI that allows continuous control of three independent finger groups, with the thumb controllable in two dimensions — totaling four degrees of freedom from thought alone. The system achieved an average acquisition rate of 76 targets per minute, with completion times under two seconds. The same system controlled a quadcopter game.

Four degrees of freedom. Seventy-six targets per minute. Those numbers matter because they’re approaching the precision needed for real game control, not just cursor movement. The game controller in your hands has more degrees of freedom than that, but not infinitely more — and the gap is closing faster than most people realize.

The consumer gaming market is moving in parallel. The BCI gaming market was valued at $144 million in 2024 and is projected to reach $927 million by 2034 at a 20.5% annual growth rate, per Polaris Market Research. That trajectory reflects genuine commercial interest, not just optimism. Game developers are starting to design with BCI inputs in mind. The integration of focus-tracking APIs into engines like Unity is already happening at the indie level.

What I think the next three years actually look like, based on the data:

• Consumer EEG gets genuinely useful as a gaming companion layer — adaptive difficulty, burnout prevention, focus-state overlays — without ever becoming a primary controller for most games

• Hybrid inputs start appearing: a controller you hold, augmented by brain signals that add a fifth or sixth axis of subtle control, like changing camera sensitivity based on your attention state

• Clinical BCI gaming expands meaningfully as more patients receive implants through Neuralink, Synchron, and BrainXBot’s growing trial programs

• New form factors for non-invasive devices — Merge Labs’ ultrasound approach, if it works, could eventually offer signal quality between today’s EEG and implants, without surgery

As we’ve tracked in our coverage of the signals that neurotech is approaching its tipping point, the field is accelerating. And as we’ve written about the consumer neurotech devices you can actually buy today, some of that technology is already in your living room — it just doesn’t look the way you’d expect.

The version where a healthy person sits down, puts on a light headset, and plays a complex game using only their thoughts — with no degraded controls, no calibration ritual, no 20% failure rate — that version is probably still years away for non-invasive devices. The version where someone with paralysis uses a brain implant to reclaim control of games and their digital life? That’s happening now, quietly, in clinical trial sites in the United States, Australia, and China.

So the question worth asking yourself isn’t “when will mind-controlled gaming be real?” It already is. The real question is: which problem matters more to you, the performance ceiling of consumer devices or the access barrier of clinical ones — and which of those do you think gets solved first? 👇

Somewhere in a server farm right now, a file containing your brain activity probably exists. Maybe you wore an EEG headband to improve your sleep. Maybe you tried a meditation device that promised to measure your focus. Maybe you played around with one of the consumer neurofeedback products that have been popping up in electronics stores like particularly ambitious Fitbits. Whatever the entry point, if you’ve used a consumer neurotech device in the last few years, there’s a reasonable chance your neural data left your skull and landed somewhere you never thought about.

This isn’t fearmongering. It’s the finding of a systematic, 100-page investigation. In April 2024, the Neurorights Foundation, a Columbia University-affiliated nonprofit led by neuroscientist Rafael Yuste, analyzed the privacy policies and user agreements of 30 consumer neurotechnology companies. The numbers were stark: 29 out of 30 companies effectively claimed ownership over every piece of neural data collected through their devices. 20 out of 30 explicitly reserved the right to share or sell that data to third parties. Only one company had any meaningful restrictions. Yuste’s word for the user agreements: “predatory.”

The conversation about what’s happening to your financial data, your location data, your health data — all of it — has been happening loudly for years. The conversation about your brain data has barely started. That’s the gap this piece is trying to close.

What neural data actually is, and why it’s different from everything else 🧠

When people hear “brain data,” they imagine a neuroscientist in a lab coat watching a glowing scan of your skull while you think about your mother. The reality is both more mundane and more alarming. Neural data is any information generated by measuring the electrical, chemical, or vascular activity of your nervous system — and it doesn’t require surgery or a hospital to collect.

Consumer EEG headbands record voltage fluctuations across your scalp. Meditation apps process those signals into emotional state estimates. Sleep trackers identify sleep stages from brain wave patterns. Even some wellness earbuds with embedded sensors now log what your auditory cortex is doing while you commute. The collection is happening quietly, continuously, and in contexts that feel nothing like a medical procedure.

California’s SB 1223, which took effect on January 1, 2025, offers the clearest legal definition of what counts: information “generated by measuring the activity of a consumer’s central or peripheral nervous system, and that is not inferred from non-neural information.” The Future of Privacy Forum calls this “the broadest conception” adopted by any U.S. state so far, because it includes signals from the peripheral nervous system (think EMG data from muscles) in addition to brain activity. 🔬

Here’s what makes neural data categorically different from other sensitive data types:

• It can identify you even when anonymized. Research cited by TechPolicy Press shows that brain patterns can be cross-referenced with social media photos to re-identify individuals, even when data has been stripped of names and metadata

• It reveals information you haven’t disclosed. Neural signals can expose mental health conditions, emotional states, cognitive patterns, and political inclinations — none of which you agreed to share

• It’s far richer than necessary. A Neurorights Foundation analysis found that consumer devices often collect roughly 10,000 times more data than the application actually uses, leaving companies with vast stores of raw neural signal they have no stated purpose for

• It cannot be reset. Your password can be changed. Your credit card can be reissued. Your brain activity pattern is yours forever, which means a breach is permanent

I think this last point doesn’t get nearly enough attention. Every data breach risk framework I’ve ever seen treats data loss as a recoverable event. For neural data, there’s no recovery. Once your EEG fingerprint is out, it’s out.

The fine print problem 🔬

It’s worth pausing on what those 30 privacy policies actually said — or didn’t say. The Neurorights Foundation’s report found that fewer than half of the companies surveyed even encrypt the neural data they collect, let alone de-identify it. Most policies were written in language vague enough to permit almost any downstream use. And, critically, most of them said nothing at all about data broker relationships.

Here’s the uncomfortable legal reality that Senators Chuck Schumer, Maria Cantwell, and Ed Markey spelled out in a 2025 letter to the FTC: devices classified as “wellness” products don’t fall under HIPAA. Neuralink, because it’s a medical device, has to comply with federal health data protection law. But the meditation headband you bought on Amazon? Under current federal law, the company can do almost whatever it wants with the signals your neurons generated. The “wellness” label is doing a lot of regulatory heavy lifting, and not in your favor.

What companies are actually doing with collected neural data varies, but the range of disclosed uses in those 30 policies included:

• Sharing with “business partners” and “affiliates” — terms broad enough to include advertisers

• Training AI models on aggregated neural datasets, with no clear limits on what those models learn about emotional or cognitive patterns

• Transferring data in the event of a “merger, acquisition, or sale of assets” — meaning your brain data is a transferable business asset

• “Research purposes” with no definition of what research, by whom, or with what oversight

The phrase that keeps appearing in these policies is some variation of “as described in this policy” — which describes almost nothing. A group of researchers at Neuroethics Canada put it bluntly: the risks are compounded by “the behavior of consumers who accept user agreements with little regard to their terms, thereby giving access to their brain data for mining, analytics, and purchase by third parties.” Which is to say: the system is working exactly as designed, and the design is not in your favor. Is this actually surprising to you, or does it feel inevitable? 💡

The law is scrambling, unevenly ⚡

The regulatory picture in 2026 is a patchwork of state laws, stalled federal proposals, and international guidelines that carry no enforcement power. The short version: some protection exists in a few U.S. states, almost none exists at the federal level, and the European framework is clearer in theory than in practice.

Colorado moved first, signing the world’s first neural data protection bill into law in April 2024 — extending the Colorado Privacy Act to cover consumer neurotech devices. California’s SB 1223 followed, effective January 2025. Montana and Connecticut (with SB 1295, signed June 2025) completed the initial group of four states with neural data law on the books.

As of early 2026, a Morrison Foerster analysis cited by Inside BCI identified active neural data bills in Virginia, Alabama, New York, Illinois, and Vermont — each taking a different approach:

• Virginia HB 654 folds neural data into the existing definition of biometric data under state privacy law

• Alabama HB 263 creates a standalone neural data statute, which is a stronger structural choice because it can’t be quietly diluted by biometric data carve-outs

• Illinois HB 5179 gives individuals a private right of action — if a company unlawfully transfers your neural data to a third party, you’re presumed to have suffered at least $10,000 in damages, without having to prove actual harm

• New York’s S9008 would treat neural data under data broker regulations, which is an interesting angle given how much data broker infrastructure already exists

The federal picture is more discouraging. Senators Schumer, Cantwell, and Markey introduced the MIND Act (S.B. 2925) in September 2025, which would direct the FTC to conduct a one-year study of neural data practices and recommend national standards. As of May 2026, the bill hasn’t moved out of committee. Directing an agency to study something is already a pretty mild intervention; failing to even pass that is a sign of how little political momentum this issue currently has.

Internationally, the EU’s GDPR almost certainly covers neural data under its “special categories” rules for biometric and health data, but there are no neuro-specific provisions. The OECD published neurotechnology governance principles in 2019. UNESCO has a draft ethics instrument under intergovernmental negotiation since 2024. In 2025, the UN Special Rapporteur on privacy urged all states to enact targeted protections. None of this is binding. France and Germany are separately drafting employment-specific laws to prohibit mandatory neurotech adoption in workplace contracts, which is at least a concrete step toward a specific risk.

The most consequential legal ruling so far came from Chile’s Supreme Court, which became the world’s first court to protect brain data under a constitutional neurorights provision. That’s genuinely remarkable. It’s also a single ruling in one country, and it required a constitutional amendment first.

Why the stakes just got higher 🧬

The case for urgency didn’t need more evidence, but 2025 delivered some anyway. In August 2025, researchers at Stanford University published results showing that an AI system translated neural signals from a woman with ALS — referred to only as participant T16 — into readable sentences in real time. The work was presented as a speech restoration breakthrough, and it is one. It’s also a proof of concept for something more unsettling: if AI can reconstruct intended speech from neural signals, the technical barrier between “brain data collection” and “thought reading” is now a matter of engineering, not science.

Japanese researchers reported a parallel advance shortly after, demonstrating “mind captioning” — generating detailed descriptions of images a person was seeing or imagining, using non-invasive brain scans combined with multiple AI systems. The accuracy wasn’t perfect. It doesn’t need to be perfect to be dangerous.

What this means for the current state of neural data privacy:

• The data being collected now may be far more decodable in five years than it is today. Companies that acquire it under current “wellness” terms will have it when the decoding tools are ready

• Re-identification will get easier. As AI models trained on neural data improve, the “anonymized” datasets sitting in company servers become progressively less anonymous

• Research cited in a 2024 Neuron paper by Farahany and Ienca found that AI can infer political ideology from brain scan data — a fact that has specific implications when neural data ends up with data brokers in politically sensitive contexts

• The workplace dimension is already arriving. Pilot programs in 2025 explored cognitive monitoring for drivers, air traffic controllers, and office workers. A peer-reviewed analysis published in EMBO Reports in 2025 flagged the potential for neural data to appear in criminal proceedings, raising urgent self-incrimination concerns

The argument that gets made most often in response to all of this is: “Well, the data is low-resolution. Consumer EEGs aren’t capturing your actual thoughts.” That’s true right now. It’s a comfort that has a shorter shelf life than most people realize.

What you can actually do today 📈

I’m not going to pretend that individual action is a substitute for systemic regulation. It isn’t. But while the regulators catch up, a few things are actually within your control.

Before buying or using any consumer neurotech device:

• Read the privacy policy before purchasing. Specifically look for: what data is collected; whether it’s sold to third parties; how long it’s retained; and what happens to your data if the company is acquired. If the policy doesn’t address those questions, that absence is itself an answer

• Check your state protections. If you’re in California, Colorado, Connecticut, or Montana, you have legal rights around neural data that you may not know about — including the right to request deletion

• Prefer companies with explicit data minimization commitments. Some companies do commit in writing to collecting only what’s necessary for the stated function. Those commitments aren’t legally watertight everywhere, but they’re better than nothing and they create an accountability record

• Be skeptical of “wellness” framing. Products that position themselves as wellness rather than medical devices are deliberately outside HIPAA’s scope. That’s a choice companies make with regulatory consequences in mind

If you’re a developer, engineer, or founder building in this space, the 7 competitive advantages piece on NeurotechMag makes a point worth internalizing: data trust is a moat. Companies that build real privacy protections in now — not as compliance theater, but as architecture — will look dramatically different from their peers when the regulatory environment tightens. And it will tighten.

As we noted in our coverage of consumer neurotech devices you can buy today, “there’s a bigger conversation emerging about regulation and ethics — because once you start collecting neural data, questions about privacy, consent, and data use matter. Very much.” That conversation is overdue. The question is whether enough people demand it before the data already collected becomes impossible to claw back.

So here’s what I’d actually like to know: if your neurotech device’s privacy policy said explicitly that your brain signals could be sold to a data broker — would you still use it? And if the answer is no, why haven’t you checked whether that’s already happening? 👇

There’s a strange thing happening in neurotech. The money is serious now. Not “hopeful seed round” serious — more like “Bezos, Gates, and OpenAI writing nine-figure checks” serious. According to the BCI Intel 2026 Annual Industry Report, more than $1.6 billion has been raised across the brain-computer interface space in 2025–2026 year-to-date. That number would have been laughable five years ago. Today, it barely raises an eyebrow.

But here’s what matters more than the headline figures: the clinical results are starting to hold up. Patients are playing chess with their thoughts. Paralyzed individuals are browsing the web using only their minds. A closed-loop brain device is stopping seizures before patients even feel them coming. This is no longer the sci-fi section of a bookstore — it’s a regulated, FDA-scrutinized, peer-reviewed reality that’s moving faster than most people realize.

If you’re a neurotech early adopter, the question isn’t whether this space produces a billion-dollar company. It’s which one crosses that line next — and whether you’re paying attention before it happens. As we covered in our piece on why neurotech is approaching a tipping point, the signals are stacking up. What follows is a look at the five companies where that stack is tallest.

Synchron: the “no open-brain surgery” pitch is actually working 🧠

If you had to design a BCI company that could navigate hospital procurement, nervous surgeons, and skittish regulators all at once, you’d probably invent something close to Synchron. Based in Brooklyn, New York, Synchron has built the Stentrode — an endovascular brain-computer interface that reaches the brain through the blood vessels rather than through a craniotomy. Threading it in via the jugular vein, the way you’d place a cardiac stent, the Stentrode sits inside a blood vessel near the motor cortex and listens.

That single design choice — no open-brain surgery — gives Synchron a compelling pitch to clinicians who would never refer a patient for a more invasive procedure. The company completed its U.S. feasibility trial and is now preparing for a full pivotal study targeting FDA Pre-Market Approval, with enrollment expected across four or more sites in 2026. Ten patients have been implanted to date across the U.S. and Australia.

The investor roster tells you something. Synchron’s $200 million Series D in November 2025, led by Double Point Ventures, brought total funding to $345 million — and the company described its valuation as “nearly $1 billion.” That round included Bezos Expeditions, Gates Frontier, Khosla Ventures, and ARCH Venture Partners. When you have Bill Gates and Jeff Bezos backing the same startup, it’s a reasonable signal that the technology has passed some serious due diligence filters.

What separates Synchron from the crowded field of implantable BCI aspirants:

• A Stentrode platform already integrated with Apple’s BCI human interface device protocol, enabling thought-controlled iPad experiences in clinical demonstrations

• Active partnership with NVIDIA Holoscan for real-time neural signal processing

• The unveiling of Chiral, described as the world’s first Cognitive AI Brain Foundation Model, announced in March 2025

• A regulatory path that’s genuinely differentiated — the low-invasiveness of the procedure reduces the barrier for a pivotal trial

The honest complication is signal quality. Threading an electrode through a blood vessel and parking it near the brain captures fewer neurons than going directly in. Synchron’s bet is that the access advantage outweighs the resolution trade-off — especially as AI signal decoding improves. So far, the clinical data suggests that bet is reasonable.

Precision Neuroscience: surface-level thinking, literally 💡

Precision Neuroscience occupies an interesting middle ground. Founded by Benjamin Rapoport, a co-founder of Neuralink who left to pursue a less invasive approach, the company’s Layer 7 Cortical Interface is an ultra-thin, flexible micro-electrode film that lays on the surface of the brain rather than penetrating it. Think of it as a contact lens for your cortex — 1,024 channels of neural recording, inserted through a small skull opening the size of a dime.

The company cleared a significant regulatory hurdle with its FDA 510(k) clearance for temporary implantation up to 30 days — a credential that allowed it to begin first-in-human implants in 2024 during routine neurosurgery. That’s strategically smart: by piggybacking on existing brain surgeries (epilepsy mapping, tumor resection), Precision is collecting real human neural data without needing to run standalone clinical trials for every implant. They’re playing the long game beautifully.

Here’s why the architecture matters for investors and technologists:

• Surface placement means no tissue damage from needle penetration — relevant for regulatory timelines and physician acceptance

• The film’s flexibility lets it conform to the brain’s surface, maintaining signal quality over time without rigid electrode drift

• The surgical simplicity of a 510(k)-cleared temporary implant creates a commercial wedge before the chronic wireless version is approved

• Precision is reportedly in the IPO conversation, alongside Synchron and Neuralink, per financial reporting from MarketWise

The road ahead is still long. Precision’s chronic wireless implant — the version that would actually live in a patient full-time — is still in development, with a first-in-human chronic test expected in 2026. That’s the version that would generate real medical device revenue at scale. Getting from temporary surgical tool to permanent neural interface is not a trivial regulatory step. But the team’s pedigree is hard to dismiss, and the Layer 7 approach may prove uniquely attractive to hospitals that already perform thousands of brain surgeries per year. 🔬

The question that keeps me interested: if your cortical interface doesn’t poke holes in brain tissue, what does long-term data show about signal stability? The answer to that question — expected over the next 18 months — may define Precision Neuroscience’s trajectory more than any funding round.

Paradromics: thinking bigger when bigger is actually necessary ⚡

Most BCI companies talk about channel counts the way car ads talk about horsepower: enthusiastically, and occasionally with more emphasis than the real-world utility justifies. Paradromics is the exception. The Austin-based company is developing the Connexus platform — a cortical implant targeting 65,000 simultaneous neural channels with a bidirectional data streaming architecture that separates it from every rival in the space.

To understand why that number matters: Neuralink’s N1 chip records from around 3,072 electrodes. A high channel count means higher resolution brain mapping, richer signal decoding, and more complex applications — from high-fidelity speech restoration to eventually reading fine motor commands for robotic limb control. The jump from 3,000 channels to 65,000 isn’t incremental. It’s a different class of ambition.

Paradromics took a real milestone in June 2025, completing its first-in-human recording during epilepsy surgery — demonstrating safe implantation, data capture, and removal in under twenty minutes. The company holds $127 million in total funding, plus approximately $18 million in NIH and DARPA grants — the kind of non-dilutive federal backing that says something about the seriousness of the technology.

A few distinguishing details worth knowing:

• The NEOM Investment Fund participated in Paradromics’ Series B in February 2025 — a signal that Middle Eastern sovereign capital is taking BCI infrastructure seriously

• The Connect-One system, Paradromics’ first chronic speech restoration implant, is on the 2026 milestone roadmap

• The company’s architecture uses separate cranial and chest components, reducing heat and size constraints in the implanted brain portion

• Paradromics has received FDA Breakthrough Device designation, which shortens regulatory review timelines meaningfully

The real risk here is execution pace. The gap between a first-in-human recording and a commercially deployable chronic implant is measured in years and clinical trial patients. Paradromics is early — earlier than Synchron, probably earlier than Precision — but the ceiling is arguably higher if the high-bandwidth thesis holds. If you believe that the most valuable BCI applications will require richly detailed neural data rather than coarse-grained signals, Paradromics is building the pipes to carry it.

Merge Labs: when Sam Altman bets on your brain 🚀

The strangest story in neurotech right now — and the one with the most complicated optics — is Merge Labs. The company emerged from stealth in January 2026 having raised $252 million from a funding round led by OpenAI, at an $850 million valuation. It was co-founded by Sam Altman, who also happens to be the CEO of OpenAI, the company that wrote the check. As the Financial Times and others noted, that circular structure raised some eyebrows. And fairly so.

But stripped of the governance drama, what Merge Labs is actually building is interesting. The company is pursuing non-invasive, ultrasound-based brain-computer interfaces — using focused ultrasound to read and potentially write neural activity through the skull, without any implant whatsoever. The scientific foundation overlaps with Forest Neurotech, another ultrasound BCI effort backed by Eric Schmidt. Caltech neuroscientist Mikhail Shapiro, who has published extensively on ultrasound neuromodulation, is part of the founding leadership.

Why is this approach worth attention?

• No surgery means a path to consumer applications that invasive BCIs simply can’t reach — at least not for decades

• Focused ultrasound has spatial resolution far superior to EEG, potentially approaching MRI-like localization without the machine the size of a small car

• The combination of Altman’s network and OpenAI’s involvement all but guarantees that AI-driven neural decoding will be a core capability from the start

• With an $850 million valuation pre-revenue, Merge Labs’ eventual IPO (whenever it comes) will move every public name in the BCI supply chain

The honest caveat: Merge Labs has no public clinical results yet. Zero. The 2026 roadmap includes “first technical demonstrations” of the platform — which is another way of saying they’re still in the proof-of-concept phase. Altman’s involvement guarantees attention, but it doesn’t guarantee the physics cooperates. Focused ultrasound for BCI is real science with real promise, but it’s less mature than the implantable approaches. Anyone calling this a sure thing is speculating, not analyzing.

That said, if the non-invasive route cracks even 20% of the signal quality that Synchron achieves endovascularly, the addressable market expands by orders of magnitude. That’s the asymmetric bet. What do you think — does a no-surgery BCI actually change mass adoption, or is the clinical population already large enough to build a big company without consumer applications?

NeuroPace: the quiet company that quietly started making money 📈

NeuroPace doesn’t show up in most “hot neurotech startups” articles, partly because it’s been around since 1997 and partly because it’s already public — listed on NASDAQ under the ticker NPCE. But that’s exactly why it belongs on this list. While everyone else is burning venture capital on feasibility studies, NeuroPace posted its first-ever positive adjusted EBITDA quarter in late 2025. That’s not a press release milestone. That’s a company proving that a brain device can actually sustain a business.

The product is the RNS (Responsive Neurostimulation) System — and if you haven’t heard of it, you’re about to understand why it’s remarkable. The RNS is a closed-loop brain device: it doesn’t just deliver electrical stimulation, it listens first. A small unit sits in the skull, monitoring brainwaves around the clock, learning the specific electrical signatures that precede a seizure. When it detects that pattern, it fires a micro-pulse to interrupt the cascade — usually before the patient experiences any symptoms at all. It’s the world’s first brain device that predicts and preempts, rather than responding after the fact.

What NeuroPace is doing in 2026 that makes it a watch-list name:

• The “Nautilus” project — a next-generation RNS with a smaller form factor designed to make the cranial surgery less invasive, targeting earlier intervention in the treatment timeline

• The adolescent mental health expansion is an adjacent path: in November 2025, the FDA cleared BrainsWay’s Deep TMS for severe depression in adolescents, validating the regulatory appetite for non-pharmacological neuro interventions. NeuroPace, with its closed-loop expertise, is well-positioned for adjacent indications

• A profitability inflection that changes the risk profile completely — this isn’t a company racing to prove viability; it’s a company proving durability

• Existing CPT codes and insurance reimbursement that eliminate one of the hardest commercial problems in medtech

The category NeuroPace occupies — call it “brain pacemakers” — is already the most mature, revenue-stable corner of neurotech. Insurance pays for it. Doctors know how to implant it. The patient population is real and large: roughly 1 in 100 people have epilepsy, and about a third of those don’t respond to medication. That’s millions of potential patients globally, with a device that’s already approved and reimbursed.

I find NeuroPace the most underrated name in this space precisely because it lacks the Musk glow or the Altman mystique. Its story is slower, quieter, and much more likely to compound. The “Nautilus” form factor, if it ships on schedule in 2026 or 2027, could meaningfully expand the implanting physician pool. And for a company that just crossed into profitability, that’s not a moonshot — it’s a roadmap. 🧬

The through-line: what to actually watch for

Every article about “companies to watch” owes you a framework for how to watch them. So here’s mine, borrowed from what I think the data actually supports in 2026.

The BCI market is splitting into two distinct tracks. The first is the clinical restoration track — paralysis, ALS, epilepsy, vision loss. Revenue comes from hospitals, reimbursed by insurance, priced at $50,000–$200,000 per implant. Synchron, Precision Neuroscience, Paradromics, and NeuroPace live here. The second track is the consumer enhancement track — productivity, gaming, mental wellness, eventually cognitive augmentation. Merge Labs is angling for this, and so are consumer neurotech device makers in the non-invasive space.

The milestones that will actually move the needle:

• Any S-1 filing from Synchron, Precision, or Merge Labs — the first neurotech IPO after Neuralink’s will reprice every name in the sector

• Pivotal trial enrollment for Synchron in 2026 — this is the last major clinical hurdle before a PMA application

• Paradromics’ Connect-One chronic speech implant results — the first high-channel-count chronic data will either validate or deflate the 65,000-channel thesis

• NeuroPace’s Nautilus launch — a smaller device means broader physician adoption, which means revenue growth that doesn’t require a category expansion

• Any regulatory signal on ultrasound BCI — the FDA hasn’t yet defined a pathway for focused ultrasound neural interfaces, and that ambiguity is Merge Labs’ biggest near-term risk

As we wrote in our analysis of what gives neurotech companies lasting competitive advantages, the moat in this space is built from IP, clinical data, and physician relationships — not from press coverage or famous co-founders. That’s worth remembering before deciding which of these five stories has staying power.

The brain is the final frontier of medicine. It has been for decades. What’s new is that the tools to navigate it are finally keeping pace with the ambition. The question is which companies build those tools well enough to still be standing when the real commercial window opens — and right now, these five are the ones making the strongest case. So: which of these bets would you be willing to place? 👇

Something happened in April 2026 that most mainstream tech outlets barely covered. A small device — a pea-sized chip carrying 520 recording electrodes — was placed on the surface of a living human brain by Dr. Murat Günel, chair of neurosurgery at Yale Medical School, as part of an early feasibility study run by a company called Science Corporation. The procedure itself was low-drama: the patient was already undergoing brain surgery, and the implant was added without requiring additional incisions or anesthesia time. The chip sat on the cortex, listened, and successfully recorded neural signals.

On paper, that sounds like a modest milestone in a field full of them. It isn’t. What makes this moment different is what the chip is designed to become — and what that says about where the entire brain-computer interface field might be heading.

Science Corp isn’t building a better electrode. It’s trying to build something that is, eventually, no longer really an electrode at all.

Why every current brain implant has the same fundamental flaw

To understand what Science Corp is attempting, you need to understand the problem that every other BCI company is quietly managing rather than solving. Put something made of metal or silicon into the brain, and the brain immediately tries to wall it off. 🔬

The sequence is well-documented. Within hours of implantation, microglia — the brain’s immune cells — detect the foreign object and begin encapsulating it. Within two to three weeks, astrocytes form a compact glial scar around the implant: a tight, insulating sheath that progressively increases the electrical impedance between the electrodes and the neurons they’re trying to record. Signal quality degrades. Over months to years, neurons in the surrounding area begin to die. The foreign body response, as it’s called in the literature, is the main reason most chronically implanted neural devices fail over time.

This isn’t a secret. Researchers have known about it for decades. The standard industry response has been to:

• Make electrodes thinner and more flexible to reduce mechanical mismatch with soft brain tissue

• Use softer materials, like hydrogels, to minimize the immune response

• Design algorithms that compensate for degraded signal as scar tissue accumulates ⚡

• Accept that long-term signal fidelity will decline and plan accordingly

Yale’s Dr. Günel has described the problem bluntly: conventional probes “cause brain damage that is likely to undermine device performance over time.” The BCI field has been engineering around that damage for two decades. Science Corp founder Max Hodak — who co-founded Neuralink before departing in 2021 — decided he’d rather solve it instead.

His proposed solution is to stop using electronics as the brain’s primary contact point, and use neurons instead. 🧠

What “biohybrid” actually means, and why it’s genuinely different

The word biohybrid gets used loosely, so it’s worth being precise. Science Corp’s full device concept combines two fundamentally different technologies: semiconductor fabrication and cell biology, with neither one subordinate to the other.

The long-term architecture works like this. A thin-film device sits on the cortical surface, resting on the brain rather than penetrating it. Embedded in the device are lab-grown neurons, derived from stem cells and genetically modified with light-sensitive proteins called channelrhodopsins — the same proteins at the heart of optogenetics research. Micro-LEDs on the chip can fire pulses of light that trigger these neurons to fire. The neurons, meanwhile, grow axons and dendrites outward from the device into the patient’s native brain tissue, forming functional synaptic connections with the circuits underneath. 💡

What you end up with, if it works, is a biological bridge. The electronics talk to the lab-grown neurons via light. The lab-grown neurons talk to the brain via chemistry — the same neurotransmitters, the same synaptic mechanisms the brain has been using for evolution’s entire run. The high-impedance glial scar problem largely disappears because there’s no metal foreign body for the brain to wall off. The neurons are the interface.

The scale potential is genuinely striking. Science Corp’s published thinking, available on the company’s website, notes the key advantages of this approach:

• A device volume of under one cubic millimeter could house a million neurons

• A million neurons, each forming multiple connections, could generate over a billion synapses

• Bidirectional communication — reading and writing neural signals — becomes possible at biological resolution, not electrode-count resolution 🚀

• Chemical neurotransmitters allow the interface to speak the brain’s native language, rather than approximating it with electricity

That’s the vision. Alan Mardinly, Science Corp’s chief science officer, has spent years building toward it with a team of about 30 researchers.

Science Corp’s first human — and what it actually demonstrated

The device placed by Dr. Günel in April 2026 is not the full biohybrid system described above. It contains no lab-grown neurons. No optogenetics. No light stimulation. It’s a recording-only platform, and as The Next Web reported, its purpose is specifically to prove that the hardware architecture can safely sit on the brain’s surface and capture meaningful signals before any biological components are introduced.

That’s actually the correct sequencing. Build the foundation. Confirm safety. Then add the biology. What the first human placement did demonstrate is significant: the biohybrid sensor successfully detected cortical activity through its living neuronal layer, validating years of preclinical animal work showing that lab-grown neurons on the device could form functional synapses with host brain tissue in rodent models. 🔬

Hodak was measured about expectations. “This is a first-in-human,” he said in the announcement. “We’re at the very beginning of understanding what this technology can do in people.”

Science Corp’s track record with biology-meets-electronics is not purely theoretical. The company’s PRIMA retinal implant — a device smaller than a grain of rice that pairs with camera-equipped glasses to restore vision in patients with age-related macular degeneration — was tested in 38 patients across 17 sites in five countries. Results published in 2025 showed 80% of patients achieved meaningful improvement in visual acuity, and 84% could read letters, numbers and words at home. Science Corp has submitted a CE mark application to the EU and expects approval by mid-2026, which would make it the first BCI company to have a product commercially available. That context matters for the brain interface work because it shows this is a team that can navigate the gap between interesting biology and regulated medical devices.

The TechCrunch profile of Science Corp’s Yale partnership is worth reading in full if you want a clear-eyed look at what the company is doing and how long it realistically expects to take. Günel’s own timeline estimate — “2027 would be optimistic” for full biohybrid trials — is an honest signal that this is basic science as much as product development.

If you work in neurotech or follow it closely, what aspects of the biohybrid approach do you find most technically credible — and what do you think remains the hardest unsolved problem?

The engineering challenges nobody is downplaying

Science Corp is not pretending this is easy. In fact, Hodak has discussed the challenges with unusual candor in public forums, and they’re worth taking seriously rather than skipping past. 🧠

Cell manufacturing is the first major one. Growing neurons reliably from stem cells, keeping them alive through the implantation process, and ensuring they form the right kinds of connections with native tissue is genuinely hard. Living cells aren’t silicon wafers — quality control operates on a completely different plane from semiconductor fabrication. Neurons are fragile. They need oxygen, glucose, and neurotrophic support. They will die if the process goes wrong, and “wrong” in cell biology can mean something that’s extremely difficult to catch before implantation.

The immune rejection problem is the second. Lab-grown neurons implanted into another person’s brain would normally trigger an immune response. The solutions Science Corp is working toward involve:

• Hypoimmunogenic stem cell lines, genetically engineered to be “cloaked” from the immune system — essentially universal donor neurons, compatible with any human patient

• Patient-derived neurons (autologous), grown from the patient’s own cells — more compatible, but takes months and currently costs over a million dollars per patient 💊

• Immunosuppressive medications during the integration window, as used in organ transplant medicine

The third challenge is the “kill switch.” Hodak has discussed this openly with TIME: if transplanted neurons were to grow uncontrollably, crowding out native cells, the system needs a way to stop them. Science Corp’s current answer is ganciclovir, an antiviral drug that could be used off-label to selectively attack the implanted cells. It’s a reasonable precaution, and the fact that they’ve thought through this failure mode is reassuring. It’s also a reminder that this technology is operating at the edge of what medicine knows how to do safely.

As NeurotechMag explored in the piece on the signals that neurotech is hitting a tipping point, capital is flowing into this field fast enough that ambitious bets are now being made at scale. Science Corp’s $230 million Series C in March 2026, at a $1.5 billion valuation, is a signal that investors believe the biohybrid bet is worth making even with these challenges unsolved.

How this fits into the BCI competitive picture

It’s tempting to treat biohybrid as just another horse in the BCI race. I think that framing undersells what Science Corp is attempting, and also overstates how soon this becomes a race in any practical sense. ⚡

Neuralink has implanted its N1 device in over 20 patients and recently expanded trials to the UK. Synchron has more than 50 patients implanted via its blood-vessel-threading Stentrode approach. Paradromics received FDA investigational device exemption for its Connexus system in late 2025, targeting speech restoration. These are all real milestones. They’re also all variations on the same fundamental architecture: put electronics near neurons, record the electrical field, decode the signal.

What Science Corp is attempting is architecturally different. Not incrementally different. The differences between a purely electronic interface and a biohybrid one are roughly:

• Signal source: electronic interfaces record field potentials; biohybrid synapses use chemical neurotransmitters

• Integration mechanism: electronics sit near neurons; biohybrid neurons become part of neural circuits

• Longevity trajectory: electronic implants degrade as scar tissue forms; biohybrid interfaces may strengthen as neurons integrate

• Stimulation physics: electronics apply voltage; biohybrid uses light-triggered neurotransmitter release — far more spatially precise 🔬

MIT’s lab has taken a different but related path. In November 2025, Professor Deblina Sarkar’s group published research in Nature Biotechnology on what they call “circulatronics”: immune cells fused with microscopic photovoltaic electronics, injected intravenously, which navigate autonomously to inflamed brain regions and self-implant, providing neuromodulation with no surgery required. It’s an entirely different application of the same core insight — that biological cells can camouflage electronics and carry them where pure engineering can’t reach.

These two approaches — Science Corp’s cortical biohybrid and MIT’s circulatronics — represent what I think is the most interesting long-term question in the BCI field: not “which electrode design wins,” but “what happens when we stop treating the brain as something electronics must learn to interface with, and start treating it as something electronics can learn to become part of.” That’s a different question. It has a different answer, and probably a different timeline.

For anyone tracking where neurotech is heading, NeurotechMag’s breakdown of the competitive advantages that define this sector is worth revisiting through this lens — because biohybrid technology, if it works at clinical scale, would fundamentally shift which advantages matter most.

Max Hodak has said that Avatar is “a pretty good reference” for how he thinks about biohybrid interfaces. That’s a provocative framing, and probably premature. But when a neurosurgeon at Yale with decades of brain surgery experience describes the concept of using transplanted neurons to protect neural circuits in Parkinson’s disease as “genius,” it’s worth pausing to take the ambition seriously rather than reflexively cycling it through a skepticism filter.

The question that I keep returning to is this: if a biohybrid implant could form a billion functional synaptic connections with a patient’s own motor cortex, would the brain eventually stop distinguishing between its own circuits and the ones that grew in from the device — and if it did, what would that mean for how we think about treating, or enhancing, the brain over a lifetime?

There’s a version of this article that starts with a grand claim about medicine being at an inflection point. You won’t find that here. What you will find are specific conditions, specific trials, specific numbers — and a clear-eyed look at what BCIs are actually doing right now versus what they might realistically accomplish by 2030.

Brain-computer interfaces have been slowly proving themselves in the clinic for years. Most of that work was invisible, running through academic medical centers and small-sample feasibility studies. But something shifted around 2024 and 2025. The trials got bigger. The results got harder to dismiss. And in some cases, the regulatory approvals arrived. What follows is the five conditions where that momentum is most real, most specific, and most worth paying attention to. Not promises. Evidence.

1. ALS, locked-in syndrome, and the restoration of speech

For people living with amyotrophic lateral sclerosis, the progression of the disease follows a specific and devastating trajectory: the motor neurons degrade, the muscles lose function, and eventually the ability to speak goes with them. Many ALS patients end up “locked in” — cognitively intact, fully aware, unable to communicate except through eye-tracking devices or painstaking letter-by-letter spelling. BCIs are changing that, and the pace of improvement in the past two years has been remarkable. 🧠

The research group led by Dr. Edward F. Chang at the University of California San Francisco published a brain-computer interface speech restoration study in Nature Neuroscience in 2025 describing a “streaming brain-to-voice neuroprosthesis” — a system that decodes intended speech directly into synthesized audio in real time. Crucially, it generates voice as the person attempts to speak, not after a processing delay. That difference matters more than it might seem: it lets users interrupt, pause, express emotion through timing, and participate in conversation as a speaker rather than a text display. 🔬

Meanwhile, the BrainGate2 consortium at Stanford and UC Davis has demonstrated speech BCIs in ALS patients achieving:

• Word accuracy rates below 5% error on a 125,000-word vocabulary

• Useful function beginning on the very first day of use, after just 30 minutes of training data

• Decoding speeds of 62 words per minute, compared to natural conversation at 160 WPM

That’s not experimental curiosity. That’s a functional communication device. The question isn’t whether this technology works — it demonstrably does. The question is how fast it can be miniaturized, made wireless, and deployed outside of research hospitals. Over the next five years, that’s the engineering challenge, and it’s more tractable than the neuroscience was five years ago. ⚡

For those curious about what brain signals BCIs use to decode speech intentions, NeurotechMag’s detailed breakdown of how the brain signals BCIs decode actually work is worth reading before going deeper here.

2. Parkinson’s disease and adaptive deep brain stimulation

Parkinson’s disease affects over 10 million people worldwide, and over 1 million in the United States alone. For decades, the standard electrical treatment — deep brain stimulation (DBS) — has worked by delivering constant electrical pulses to specific brain regions. Constant. As in, on all the time, at a fixed frequency, regardless of what the patient’s brain is doing at any given moment. A pacemaker for the brain, yes — but one with no ability to sense whether the heart is already beating steadily. 💡

That changed on February 24, 2025. Medtronic received US FDA approval for BrainSense Adaptive DBS, which Medtronic described as the world’s first commercially available adaptive deep brain stimulation system — and one of the largest commercial launches of brain-computer interface technology ever. The system does something conventional DBS couldn’t: it reads beta oscillations from the patient’s own brain in real time and adjusts stimulation accordingly.

Why beta oscillations? Because in Parkinson’s disease, pathological beta waves (typically 13-30 Hz) in the basal ganglia correlate closely with motor symptoms including tremor and rigidity. When beta power is high, symptoms are worse. When it drops — usually after dopamine medication takes effect — symptoms ease. Conventional DBS stimulated constantly regardless of that state. Adaptive DBS fires when the brain signals it’s needed. The clinical implications are:

• Fewer side effects caused by unnecessary over-stimulation

• Longer device battery life, meaning less frequent replacement surgeries

• More responsive, personalized symptom control across the day as symptoms fluctuate ⚡

• A genuine feedback loop between the patient’s neural state and the therapy being delivered

The ADAPT-PD trial, which underpinned the FDA approval, used a randomized crossover design where each patient served as their own control. Those are the kinds of results that get taken seriously, and they should. Adaptive DBS is a BCI — it reads brain signals and acts on them. It just happens to look less futuristic than a chip you can see on a head. 📈

3. Drug-resistant epilepsy and seizure prediction

About 30-40% of all epilepsy cases are drug-resistant — meaning two or more anti-seizure medications have failed to control seizures. That’s approximately 1.2 million people in the United States living with epilepsy that medication can’t adequately manage. For many of them, the alternative was brain surgery to remove the seizure-generating tissue. Sometimes that works. Sometimes it doesn’t. Sometimes surgeons can’t do it safely without risking memory, speech, or vision. 🔬

NeuroPace’s RNS System is a closed-loop BCI that takes a different approach entirely. It monitors each patient’s brain activity continuously, learns their individual “seizure fingerprint,” and delivers brief electrical pulses the moment it detects that fingerprint emerging — before the seizure fully develops. No tissue removal. No constantly-on stimulation. Personalized, real-time response to the patient’s own neural patterns.

The three-year data presented at the American Academy of Neurology’s 2025 Annual Meeting are frankly striking:

• 82% median seizure reduction at three years in 324 patients at 32 centers — the largest FDA-reviewed prospective neuromodulation trial in the field

• 42% of patients remained seizure free for six or more consecutive months

• Seizure reduction appeared to improve over time, rather than plateau or decline 💊

This isn’t the future of epilepsy care. It’s the present. What the next five years brings is expansion of indications — NeuroPace’s NAUTILUS study is already testing the RNS System in generalized epilepsy, not just focal epilepsy — and miniaturization that makes the device less burdensome to implant and maintain.

One thing I find genuinely underappreciated about the RNS system: it’s also a long-term neural data recorder. Every seizure event, every stimulation response, every pattern over years gets logged. That’s a dataset that could eventually teach us more about seizure biology than a hundred small academic studies combined. The treatment device is also a research instrument. That’s elegant, and it matters.

What would you do if you could see a seizure coming 30 seconds before it happened? Would you drive a car differently? Would you plan your day differently? These are the questions 1.2 million people might realistically be asking within a few years.

4. Treatment-resistant depression and the closed-loop mood circuit

Major depressive disorder (MDD) is the largest cause of psychiatric disability worldwide. And treatment-resistant depression — meaning depression that fails to respond to at least two adequate medication trials — affects roughly a third of all MDD patients. That’s not a small group of edge cases. That’s tens of millions of people. 🧠

Deep brain stimulation for depression has had a complicated history. Early open-label studies were genuinely dramatic — many patients responded strongly to stimulation of the subgenual cingulate cortex or the ventral capsule/ventral striatum. Then the randomized controlled trials came, and the results were inconsistent. The reason, researchers now suspect, is that the stimulation was fixed. It didn’t respond to the patient’s moment-to-moment neural state. It just pushed constantly, like turning on a faucet and leaving the room.

A landmark study published in Nature Medicine tested a different model. A team at UCSF identified a neural biomarker — specifically, high gamma activity in the right amygdala — that correlated reliably with the patient’s worst depression symptoms. They then implanted a NeuroPace RNS device programmed to detect that biomarker and deliver stimulation only when it was detected, in the region of the brain that stimulation consistently improved her symptoms. The approach:

• Personalized to her specific neural signature of depression, not a generic protocol

• Detected her individual high-symptom states automatically

• Delivered stimulation only when needed, avoiding the habituation problem seen in constant DBS ⚡

• Produced rapid and sustained improvement, per the Nature Medicine report

That was one patient. One case report. And researchers are careful to say it can’t be generalized yet. UCSF now has larger trials running. But what that study demonstrated is a method — one that solves the core problem that sank earlier depression DBS trials. The next five years will reveal whether personalized closed-loop depression treatment generalizes beyond the patients who happen to have clean, detectable biomarkers.

Depression research is where I’d argue BCI is the most philosophically interesting. Because the question of what a neural biomarker of depression “is” — whether it’s a signature of a brain state, or a cause of it, or a consequence of it — matters enormously for whether stimulating it actually helps or just suppresses a signal while the underlying condition continues. That complexity deserves honest acknowledgment, and the researchers involved in these trials are refreshingly aware of it. 📈

5. Stroke rehabilitation and rewiring the motor cortex

Every year, roughly 15 million people worldwide suffer a stroke. About 5 million are left with permanent disability. Of those, a significant proportion have motor deficits — partial paralysis of an arm, a hand, impaired walking — that conventional physical therapy improves only partially. The brain after stroke can reorganize. Neuroplasticity is real. The problem is that traditional rehabilitation can’t reliably direct that reorganization, and the window for it may be limited. 🌱

BCI-based stroke rehabilitation works on a specific principle: the brain responds more strongly to its own intentions. If a paralyzed stroke patient imagines moving their affected hand, that generates a characteristic EEG pattern — a drop in beta and alpha oscillations in the motor cortex. BCIs detect that motor intention and immediately trigger the corresponding movement via a hand exoskeleton or functional electrical stimulation. The body moves in response to the brain’s intention, rather than being moved passively.

The clinical hypothesis, increasingly supported by evidence, is that this contingent feedback loop — brain signals intention, device executes movement, proprioception feeds back to brain — promotes the kind of targeted neuroplastic reorganization that conventional therapy can’t as reliably produce. A 2025 meta-analysis published in PMC examined BCI stroke rehabilitation trials and found:

• A recent large RCT of ischemic stroke patients (n ≈ 296) showed BCI rehabilitation added to standard care produced significantly greater upper limb motor improvement than standard care alone

• A separate 2025 RCT found greater Fugl-Meyer score improvement in BCI groups plus measurable neuroplastic changes in brain activation patterns

• Motor gains from BCI-augmented therapy were not just measured on the day of training — they persisted at follow-up assessments 🔬

The most realistic 5-year trajectory for BCI stroke rehabilitation is not implantable devices — it’s better non-invasive EEG headsets that are cheap enough, accurate enough, and easy enough to set up that stroke rehabilitation clinics can use them routinely. The technology is close to ready. The bottlenecks are cost, insurance coverage, and clinical training. Those are frustrating bottlenecks, but they’re more solvable than the neuroscience was five years ago.

This is also an area where the neurotech tipping point signals that NeurotechMag identified are directly relevant: as consumer-grade EEG devices get better and cheaper, the gap between laboratory rehabilitation BCIs and clinical-grade versions narrows quickly. That gap is the one that matters for stroke patients, because the difference between “this exists” and “this is available at my local rehab center” is the only difference that changes lives.

Among all five conditions here, stroke rehabilitation may be the one where BCIs become broadly accessible soonest — not because it’s the most scientifically dramatic, but because the technical requirements are the lowest and the patient population is the largest. Sometimes the most important breakthrough isn’t the hardest one to achieve. It’s the one that reaches the most people.

So here’s the question worth sitting with: if you had to pick one of these five conditions to see a genuine BCI-based treatment approved and available at most major hospitals within five years, which would you bet on — and why?

Something remarkable happened in January 2024. A 29-year-old man named Noland Arbaugh, paralyzed from the shoulders down after a diving accident, lay in a surgical suite at the Barrow Neurological Institute in Phoenix while a robot precisely threaded 64 ultra-thin filaments into his motor cortex. Each filament, thinner than a human hair, carried 16 electrodes — 1,024 electrodes in total. When he woke up, he was still paralyzed. But a few weeks later, he was browsing the web, playing chess online, and streaming Mario Kart on Twitch. Using nothing but his thoughts.

That device is a brain-computer interface, or BCI. And while Neuralink’s version dominates the headlines, BCIs are a whole field that has been quietly building since German psychiatrist Hans Berger first recorded human brain waves with an EEG machine in 1924. The concept isn’t new. The pace is.

If you’ve been curious but confused about what BCIs actually are, how they work, and whether they’re coming to a Best Buy near you, this piece is for you. No jargon. No condescension. Just the real story — complexity included.

What a brain-computer interface actually does

At its simplest, a BCI is a system that reads brain activity and turns it into a command a computer can execute. Think of it as a translator between neurons and machines. 🧠

Your neurons fire. The BCI intercepts those signals. An algorithm decodes what those signals mean. And then something happens: a cursor moves, a robotic arm lifts, a synthesized voice speaks the word a paralyzed person intended to say. The pipeline always works in three stages:

• Signal acquisition: electrodes pick up electrical activity from neurons, either on the scalp, on the brain’s surface, or inserted directly into brain tissue

• Signal processing: software filters noise and interprets patterns using machine learning models trained on neural firing data

• Output: the decoded intention becomes a real-world action — moving a cursor, typing a letter, controlling a prosthetic limb ⚡

What makes BCIs genuinely surprising is that the brain doesn’t need to physically do anything. A completely paralyzed person can imagine reaching for a glass of water, and the BCI picks up the motor intention — the neural “draft” of that movement — and acts on it. As a 2025 review in Brain-X confirmed, neurons in the motor cortex encode intended movement even when no movement occurs. The brain is already sending the memo. BCIs learned to read the mail. 💡

The signals BCIs most commonly target include alpha waves (8-12 Hz, tied to relaxed attention), beta waves (13-30 Hz, prominent during focused movement), and sharp spikes called action potentials fired by individual neurons. If you want to understand what these signals look like and how neurotech decodes them in detail, NeurotechMag’s breakdown of what your brain signals actually mean and how BCIs decode them covers each type thoroughly.

Different applications need different signals. A consumer headset for focus tracking is happy with alpha waves. A surgical implant that needs to distinguish between “grip” and “pinch” needs something far more precise. That’s where the spectrum between invasive and non-invasive devices gets important.

Invasive vs. non-invasive: the tradeoff that defines everything

Not all BCIs are created equal, and the differences aren’t cosmetic. 🔬

Non-invasive BCIs use sensors outside the skull. The most common technology is electroencephalography (EEG), which measures the combined electrical activity of millions of neurons through electrodes on the scalp. EEG is cheap, safe, and widely available. It’s also blurry — skull and scalp tissue scatter the signals, so EEG captures broad cognitive states (focus, relaxation, stress) far better than it decodes specific motor commands. Consumer devices like the Muse headband, the Myo armband, and the Neurosity Crown sit in this category, and a full look at what you can actually buy today is worth reading in NeurotechMag’s 5 neurotech devices you can actually buy right now.

Invasive BCIs go inside, with two main subtypes:

• Electrocorticography (ECoG): electrodes placed on the brain’s surface, under the skull but not piercing the tissue — higher resolution than EEG, lower surgical risk than full implants

• Intracortical implants: electrodes inserted into brain tissue itself — highest signal quality, highest risk, narrowest patient population willing to agree to the procedure

Then there’s a middle ground that has gotten quietly compelling. Synchron, backed by Bill Gates and Jeff Bezos, threads its Stentrode device through blood vessels into position near the motor cortex — no open-skull surgery required. Being less invasive means faster regulatory approval and lower surgical risk, though it also means lower signal resolution. Synchron has been implanting patients since 2019, treating people while Neuralink was still running its feasibility studies.

Precision Neuroscience, founded by a former Neuralink co-founder, makes a thin film of electrodes that slides through a small slit in the skull’s dura. In April 2025, Precision’s device received FDA 510(k) clearance — the first commercial authorization for a cortical interface of this type — with implantation durations approved up to 30 days. 🚀

The tradeoff is stark and real: more invasive means better signal, which means more precise control, but also more surgical risk and a narrower group of people who will realistically consent to it.

Who’s building this, and what they’re actually building it for

Neuralink dominates the conversation, partly because Elon Musk is involved and partly because the company has been unusually transparent about its human trial results. But the competitive field is wider than most people realize. 📈

As Fortune’s detailed reporting on Neuralink’s PRIME Study revealed, the company has now enrolled 21 participants across clinical trials in the US, Canada, the UK, and the UAE. All participants have paralysis or ALS. Noland Arbaugh, the first implant patient, uses his chip about 10 hours a day. He named it “Eve.” He’s now studying pre-calculus, running a business, and speaking at tech conferences. That’s not a lab demonstration — it’s a transformed daily life.

Meanwhile, the broader competitive field includes:

• Synchron, treating patients via its blood-vessel approach since 2019 ⚡

• Precision Neuroscience, freshly FDA-cleared in 2025, targeting ALS communication

• Paradromics, which secured over $105 million in funding including NIH and DARPA grants, and completed its first human implant with a system targeting speech restoration

• BrainGate, an academic consortium that has been running intracortical implant trials for more than two decades, longer than any commercial player

Grand View Research estimated the global invasive BCI market at $160 billion in 2024, driven primarily by paralysis, rehabilitation, and prosthetics. IDTechEx puts a more conservative number on the broader market, forecasting it to grow to $1.6 billion by 2045. These estimates feel like they’re measuring different things — and they probably are. What’s clear is that serious capital is chasing this field. Neuralink alone has reportedly raised over $650 million.

Here’s a question worth asking yourself now: if a paralyzed person using a BCI can achieve cursor control speeds that approach those of an able-bodied person using a standard mouse, at what point does “assistive technology” become something the rest of us might also want? 🧠

The medical applications that are working right now

BCIs aren’t waiting to become medically useful. They are medically useful, in specific and meaningful ways. 💊

The clearest wins are in communication and motor restoration for people living with:

• ALS (amyotrophic lateral sclerosis), which destroys motor neurons and can leave patients unable to speak or move

• Cervical spinal cord injuries causing quadriplegia

• Stroke rehabilitation, where non-invasive BCIs help retrain damaged neural pathways by reinforcing the brain’s intention-movement feedback loop

• Epilepsy, where closed-loop systems detect seizure onset in real time and respond before the patient is even consciously aware

Speech restoration is one of the most striking application areas. In 2024, speech neuroprostheses — BCIs that decode intended speech from cortical signals and convert them into synthesized voice or text — made significant advances in clinical settings. According to the 2025 review published in Brain-X, researchers have now developed speech BCIs capable of decoding Mandarin tonal language, not just English. That matters. Mandarin is notoriously harder to decode because pitch changes the meaning of words, not just their sound. Getting it right requires a level of decoding precision that would have seemed implausible five years ago.

The frontier is closed-loop systems: BCIs that don’t just read signals but send them back. In 2025, researchers at Tsinghua and Tianjin Universities unveiled a two-way adaptive brain-computer interface that incorporates feedback to the brain, creating a dual-loop system. Traditional BCIs only interpret signals — this one reads and writes simultaneously. The potential applications for Parkinson’s disease, severe depression, and post-stroke rehabilitation are significant enough to take seriously, even if the clinical path is still long. 🔬

What excites me most isn’t the glamorous applications. It’s the quieter ones: real-time cognitive load monitoring for Alzheimer’s patients, home-based seizure tracking through non-invasive EEG, closed-loop systems that adjust brain stimulation before a tremor fully develops. These aren’t headline-grabbing. They’re genuinely useful — which is often a more durable kind of important.

The part nobody likes to discuss: your neural data and who owns it

Here’s where it gets uncomfortable, and where optimism needs some honest pressure applied. 🔬

BCIs collect the most intimate data that exists: the real-time electrical activity of your brain. Neural data can reveal emotional states, intentions, stress levels, and potentially far more as decoding algorithms improve. A 2024 essay in PLOS Biology identified the sharpest concerns:

• “Brainjacking”: unauthorized access to neural data by bad actors, corporations, or government entities seeking to exploit emotional states or infer intentions

• Cognitive inequality: enhanced individuals gaining unfair advantages in education, hiring, or high-performance work environments

• Mental monoculture: the risk that standardized brain interfaces could nudge cognition toward conformity, reducing the diversity of human thinking over time

• Inauthenticity: the genuinely hard question of whether a thought influenced by a device is still fully yours

The regulatory picture in the US is patchy. Minnesota has gone furthest: Governor Tim Walz signed legislation in May 2024 imposing civil and criminal penalties for unauthorized use of consumer neural data. Colorado has included neurological data under its state Privacy Act. California passed a neural privacy bill in September 2024. But at the federal level, consumer BCIs remain largely unregulated — a gap that the NeuroRights Foundation, based in New York City, has been pushing hard to close.

Stephen Damianos, executive director of the NeuroRights Foundation, has been direct: this isn’t a future problem. It’s a today problem. Walter Johnson, a postdoctoral fellow at Stanford Law School’s Center for Law and the Biosciences, has noted that tech companies’ track records in other areas of data privacy don’t inspire confidence. That’s a polite way of saying: if they couldn’t protect your photos, why would they protect your thoughts?

I think the framing that Columbia neuroscientist Rafael Yuste put forward in Nature back in 2017 still holds up better than anything proposed since: four pillars of concern — privacy and consent, agency, augmentation pressure, and bias. Every uncomfortable question the industry still hasn’t answered maps neatly onto one of those four.

Where this goes, and what you should actually expect

Here’s what the realistic near-term picture looks like, stripped of both hype and excessive skepticism: 🌱

• Medical implants will expand carefully, with more patients in trials through 2026-2027 and the first commercially available devices potentially arriving in the early 2030s

• Non-invasive consumer devices for focus, sleep, meditation, and accessibility will grow faster — the technology is mature enough, the regulatory bar is lower, and the market appetite is real

• AI integration is the key accelerant — better machine learning means better decoding from cheaper hardware, which is the unlock that scales this technology beyond hospital settings

• Regulatory frameworks will lag, creating a window where neural data collection meaningfully outpaces protection

As NeurotechMag explored in 6 signals that neurotech is reaching a tipping point, CES 2026 already featured a real-time, consumer-friendly EEG device from LumiMind designed for everyday life, not hospitals. That’s not a prototype. That’s a product roadmap. 📈

China deserves specific attention. Multiple Chinese government ministries have laid out a 5-year roadmap to make China a global BCI powerhouse by 2030, integrating research, manufacturing, and clinical deployment. The two-way BCI from Tsinghua and Tianjin is that strategy in motion. Geopolitical competition has a long history of accelerating technology timelines — for better and for worse.

What BCIs ultimately represent is a new interface layer between human consciousness and the digital world. Every layer we’ve added before — the keyboard, the mouse, the touchscreen, voice commands — changed how we think, work, and relate to each other in ways we only understood in retrospect. The brain is the most intimate interface layer imaginable. That’s what makes this worth paying close attention to, long before any of us are considering a neurosurgery appointment.

So here’s the question worth actually sitting with: if a non-invasive BCI headset could give you measurably faster reaction times, better sustained focus, and a documented learning edge — would you wear it to work? And if your employer provided one, would you feel like you had a real choice in the matter?

You open a neurotech article and, by the third paragraph, you’re drowning. There’s EEG next to fMRI, then someone mentions spiking neural networks, and before long you’re staring at the phrase “closed-loop neuromodulation” like it owes you money. You close the tab. You go make coffee. Neurotech loses another curious mind to vocabulary overload.

This happens constantly, and it’s a shame — because the actual story of what’s happening in brain-computer interfaces right now is one of the most fascinating in all of technology. Paralyzed people controlling computers with their thoughts. Earbuds that track your focus in real time. A chip at Columbia University with 65,536 electrodes streaming neural data wirelessly. The story is extraordinary. The jargon is just the door you have to get through to reach it.

So here’s a field guide. Not a glossary, not an exhaustive textbook — a practical map for following neurotech news intelligently, week after week, without needing to memorize Latin root words.

Start with the two things the field actually does

Almost everything in neurotech falls into one of two buckets: reading the brain, or writing to it. Get that distinction locked in and half the jargon problem disappears.

Reading the brain means measuring electrical or metabolic activity — figuring out what’s happening in there. The main tools are:

• EEG (electroencephalography): Electrodes on the scalp pick up electrical signals. Fast, cheap, portable. The signal is noisy because it has to travel through skull and skin, but it’s improving fast. This is what most consumer neurotech uses — your meditation headbands, your focus-tracking earbuds.

• fMRI (functional MRI): Measures blood flow as a proxy for brain activity. Incredible spatial resolution (it can pinpoint activity to within a few millimeters 🔬), but it’s slow and you have to lie perfectly still in a giant magnet. Nobody is shipping a consumer fMRI headset anytime soon.

• ECoG (electrocorticography): Electrodes placed on the brain’s surface, not the scalp. Used in surgery. Much cleaner signal than EEG.

• Single-unit recording: Tiny electrodes that pick up signals from individual neurons. This is what Neuralink does. Extremely precise, requires surgery.

Writing to the brain means delivering some kind of signal into it to change how it behaves. Tools here include:

• DBS (deep brain stimulation): Surgically implanted electrodes send electrical pulses to specific brain regions. Already FDA-approved for Parkinson’s disease, with over 180,000 patients treated worldwide 🧠.

• TMS (transcranial magnetic stimulation): A magnetic coil outside the skull induces an electric current inside it. No surgery required. Wikipedia’s entry on TMS is actually one of the cleaner technical explainers out there if you want to go deeper.

• tDCS (transcranial direct current stimulation): A weak electrical current passes through the scalp. Cheap, simple, and wildly controversial in terms of efficacy outside lab settings.

Once you know whether a story is about reading or writing, everything else is detail. I think this mental split is the single most useful thing a neurotech newcomer can learn.

Learn the invasive/non-invasive divide — it matters more than you think

The phrase you’ll see everywhere is “invasive vs. non-invasive,” and it’s not just a medical technicality. It’s the central tension in the entire field right now 🔬⚡.

Invasive BCIs put electrodes inside the skull or on the brain’s surface. Neuralink’s N1 chip, for example, sits in the motor cortex and uses 1,024 electrodes to record individual neuron spikes. Blackrock Neurotech’s Utah Array has been implanted in dozens of patients since 2004. Precision Neuroscience’s Layer 7 interface is a wafer-thin film that slides across the cortical surface rather than penetrating it. The upside: extraordinary signal quality. The downside: brain surgery.

Non-invasive BCIs gather signals from outside the skull. The signal is messier — picture trying to hear a whispered conversation through a concrete wall — but no one has to open your head. Consumer EEG devices from companies like Neurable and Muse sit here. So does Synchron’s Stentrode, which is technically a middle path: it’s implanted inside a blood vessel near the motor cortex, which counts as a surgical procedure but not traditional brain surgery.

Why does this distinction matter when you’re reading news? Because the claims you should expect from each category are very different:

• Non-invasive systems: useful for attention tracking, meditation feedback, sleep monitoring, some assistive communication — but don’t believe hype about reading thoughts precisely

• Invasive systems: capable of impressive feats (typing at 40 words per minute using thought alone, in a 2023 Stanford trial), but still experimental, still expensive, still requiring neurosurgeons

When a headline says “mind-reading device,” your first question should be: invasive or non-invasive? The answer tells you immediately whether you’re reading about a clinical trial or a consumer gadget.

The jargon that trips people up most — decoded

Let’s go term by term through the phrases that make neurotech articles unreadable to anyone outside the field. Think of this as cheat codes 🎮.

Neural decoding sounds mystical. It just means using an algorithm to translate brain signals into a useful output — a cursor movement, a word, a robotic arm command. The brain produces electrical patterns. The decoder is a piece of software, often a machine learning model, that’s been trained to recognize which pattern means what.

Signal-to-noise ratio (SNR) comes up constantly. Your brain produces tiny electrical signals. The environment produces electrical noise from power lines, your phone, your muscles, everything. Getting a clean brain signal means improving SNR — filtering out everything that isn’t brain. This is why Neurable’s engineering team uses proprietary AI to clean the signal before interpreting it.

Neuromodulation is the umbrella term for anything that deliberately changes how the brain or nervous system is functioning. DBS is neuromodulation. TMS is neuromodulation. Certain drugs are technically neuromodulation. If a company says it’s “in neuromodulation,” that’s a broad church — they could be making anything from surgical implants to wellness headbands.

Neuroplasticity is the brain’s ability to physically rewire itself in response to experience or stimulation. This is why BCI training takes weeks: you’re not just teaching software, you’re changing the brain itself.

Closed-loop vs. open-loop: Open-loop systems deliver stimulation on a fixed schedule regardless of what the brain is doing at that moment. Closed-loop systems sense brain state first, then adjust stimulation in response. Closed-loop is harder to engineer but dramatically more effective for conditions like epilepsy. When you read “closed-loop DBS,” that’s a significant technical achievement.

A few more that deserve quick treatment:

• Motor imagery: Imagining movement without actually moving. BCIs for paralyzed users often rely on this because the motor cortex still fires even when muscles can’t respond

• P300: A specific brain wave pattern that appears about 300 milliseconds after a surprising or relevant stimulus. BCIs exploit this for spelling systems — the brain lights up for the target letter, and software spots which one

• Artifact: In this context, noise that looks like a brain signal but isn’t — from blinking, muscle movement, or electrical interference. Removing artifacts is a major chunk of signal processing work

Where to actually read the news without losing your mind

Here’s the real practical problem: neurotech content splits into two extremes. Academic papers are dense and assume you already have a PhD. Press releases are breathless and assume you’ll believe anything. Finding the middle is the skill 🧠📈.

A few sources that genuinely hold the line:

• IEEE Spectrum’s neurotechnology coverage: Written for technical readers but edited for clarity. Reliable on what’s actually working vs. what’s being claimed.

• The Transmitter: A relatively new nonprofit journalism outlet covering neuroscience with genuine rigor. Exceptional for understanding the science behind the headlines.

• NeurotechMag: A weekly newsletter covering science, business, and research with a sharp eye on what matters. If you’re reading this, you’ve already found it.

• PubMed and bioRxiv: Yes, they’re dense. But the abstract of almost any paper is readable with a little patience, and it tells you what was actually tested rather than what a PR team claims.

For community and conversation, NeurotechX is an open community of researchers, developers, and enthusiasts who share papers, tools, and honest takes. Reddit’s r/neuroscience and r/BCI are less rigorous but useful for getting a pulse on what newcomers are confused about — which is often genuinely illuminating.

One useful habit: when you read a news story, find the original paper. Most science journalists link to it. Skim the abstract. Look at the sample size. If a “mind-reading” study involved six participants over two weeks, that context matters enormously. Does the finding seem to match the headline? That one question, asked consistently, will make you a significantly better reader of neurotech news within a month 🚀.

The hype problem — and how to calibrate for it

Neurotech has a publicity machine that tends to run a few years ahead of the actual technology, and there’s a reason for that: the stakes are high, the funding rounds are large, and the human stories are genuinely moving. A paralyzed person typing with their thoughts is extraordinary. It’s also, right now, still experimental, still happening in research settings with trained teams, and still a long way from something you could buy or prescribe.

Anna Wexler, a bioethicist at the University of Pennsylvania’s Perelman School of Medicine, has pointed out something worth keeping in mind: even if an invasive BCI allowed a healthy person to type 5-10% faster, most people probably wouldn’t sign up for brain surgery to get it. The practical value of consumer implants remains genuinely unclear, and getting people’s hopes up irresponsibly risks backlash when the technology inevitably fails to match the hype.

Some things worth watching for when calibrating your skepticism:

• Sample size matters enormously — a trial with six participants is interesting, not definitive

• “FDA breakthrough device designation” sounds major but is actually fairly early-stage recognition, not approval

• Consumer EEG is improving but not magic — focus-tracking headphones are real; thought-to-text on a smartphone is not imminent

• Funding rounds signal investor belief, not proven technology — in 2025, disclosed neurotech funding surpassed $1.3 billion, led by Neuralink’s $650M round, but capital doesn’t equal clinical validation

The goal isn’t cynicism. Neurotech is doing genuinely extraordinary things. DBS already helps hundreds of thousands of people with Parkinson’s. BCIs are letting people with ALS communicate again. The field is real and the progress is real. The goal is calibrated enthusiasm — excited about what’s actually working, patient about what isn’t yet 🧬.

For more context on which neurotech developments are real and which are dressed-up press releases, the NeurotechMag piece on 6 signals that neurotech is reaching a tipping point gives a useful framework for thinking about genuine inflection moments vs. noise. And if you want to understand what signals the brain actually produces — the raw biological inputs all this technology is working with — 7 Signals Your Brain Is Giving You is worth your time.

The single best thing you can do right now: pick one area — consumer EEG, invasive BCIs, neuromodulation, whatever genuinely interests you — and follow just that thread for the next two months. Read everything you can in that one lane. The vocabulary will start feeling familiar. The players will start having faces. The hype will start looking different from the progress.

What part of the neurotech space do you find most confusing — or, honestly, most overhyped? Drop it in the comments.

Your boss already tracks your keystrokes, your Slack activity, your screen time, maybe even your webcam during remote hours. Now imagine they could track your attention levels, your emotional state, your mental fatigue — in real time, via a pair of inconspicuous earbuds. That’s not a dystopian thought experiment. That’s what Emotiv’s MN8 system already does: it tucks brain-scanning EEG sensors into Bluetooth earbuds designed for office workers, including those working remotely.

The technology is here. The deployments are real. And the debate about what any of this means for workers, privacy, and human dignity is only beginning to get loud enough for regulators to hear it. Strap in — or rather, strap on — because this one’s going to get complicated. 🧠

What workplace neurotech actually does (and doesn’t do)

Let’s kill the mind-reading fantasy right away, because the reality is both less dramatic and more troubling. Current neurotech doesn’t read minds. Sensors detect electrical activity across different areas of the brain, and the patterns in that activity can be broadly correlated with different feelings or physiological responses — stress, focus, or a reaction to external stimuli. Think of it like a mood ring with a PhD, not a window into your thoughts.

The technology most commonly used in workplace applications is electroencephalography, or EEG — a method of measuring electrical signals from the brain through electrodes placed on the scalp. EEG has been around for about a century, commonly used in medicine and neuroscience research, where subjects might have up to 256 electrodes attached to their scalp with conductive gel for precise spatial resolution. Commercial workplace devices use far fewer channels, sacrificing resolution for wearability.

So what can these stripped-down sensors actually tell an employer? Quite a bit, as it turns out:

• Fatigue and alertness levels — whether a worker is attentive or nodding off 💤

• Cognitive load — how mentally taxed someone is during a task

• Stress signals — elevated arousal patterns that correlate with anxiety

• Emotional responses — positive or negative reactions to stimuli, useful in contexts like training sessions or product evaluation

• Focus quality — whether someone is “in the zone” or scattered

James Giordano, chief of neuroethics studies at Georgetown University Medical Center, is emphatic about the stakes: “This is not sci-fi. This is quite real.” And real is exactly what makes people nervous. 😬

What’s interesting, though, is that the companies building these tools aren’t pitching them as surveillance. They’re pitching them as wellness. Emotiv frames its enterprise offering around productivity and employee well-being. The narrative is: we’re not watching you, we’re helping you. Whether workers experience it that way is another matter entirely.

Real deployments in real workplaces

This debate isn’t theoretical. Pilot projects using EEG and other neural monitoring technologies are already happening in offices, factories, farms, and airports — and have been for several years. The use cases range from the safety-focused to the productivity-obsessed.

Israeli startup InnerEye is currently partnering with a handful of airports around the world to help human reviewers analyze X-ray scanner images more efficiently using brain signal data. Workers wear a lightweight EEG headset while images flash on screen at three per second. The system detects which images triggered a neural response indicating recognition, even when the worker couldn’t consciously articulate it. The brain spotted something before the conscious mind did. That’s genuinely remarkable. 🔬

Then there’s Microsoft’s Human Factors Team, which used EEG data to measure cognitive load during virtual meetings. They found that participants in traditional video conferencing setups often exhibited higher levels of cognitive load compared to those using Together Mode, a feature that creates a shared virtual space simulating a physical meeting environment. The brain data directly influenced product design. That’s a relatively benign application — but it’s also a template for something more invasive.

The global market for neurotech is growing at a compound annual rate of 12% and is expected to reach $21 billion by 2026. That kind of money attracts ambition, and ambition doesn’t always stay within ethical guardrails. 📈

The industries already deploying some form of neural monitoring include:

• Mining and heavy industry (fatigue detection for safety)

• Finance (cognitive performance tracking)

• Aviation (alertness monitoring for pilots and air traffic controllers)

• Healthcare (burnout detection and workload assessment)

• Tech (cognitive load measurement, UX research)

The United Kingdom’s Information Commissioner’s Office predicts neural monitoring will be common in workplaces by the end of the decade. Common. Not experimental. Not fringe. The default.

The “neurodiscrimination” problem no one’s talking about enough

Here’s where it stops being an interesting tech story and starts being a genuinely alarming civil rights conversation. Nita Farahany, Robinson O. Everett Distinguished Professor of Law and Philosophy at Duke University and author of The Battle for Your Brain, has probably thought harder about this than anyone alive. She calls the bundle of rights at stake “cognitive liberty” — the right to mental privacy, freedom of thought, and self-determination over your own brain.

Farahany warns that this is not a science fiction book. This is not about the future. This is about a future that has already arrived, and the question is just the scale it will reach before we do something about it.

The most immediate worry is neurodiscrimination — the use of brainwave data to make employment decisions that workers have no recourse against. There is a risk that brainwave data could reveal signs of cognitive decline, potentially influencing decisions about whether to fire somebody — based on data the person never consented to share in that context.

Think about that. Your theta waves betray early-stage attention deficit patterns. Your stress response spikes every time your manager enters the room. Your focus drops measurably after 2pm. All of that becomes a permanent record, and potentially a reason not to promote you — or to manage you out. The performance review of the future might not be a conversation. It might be a graph. 😤

A study from April 2024 examined policy documents from 30 companies offering neurotechnology devices and found that 60% of these companies failed to inform consumers about how their neural data is managed or what rights they have over it, even in countries with data protection laws. That data opacity isn’t a bug — it’s baked in to an industry that benefits from ambiguity.

What does the concept of cognitive liberty mean to you? Would you consent to wearing a neural monitoring device at work if your employer framed it as optional but made it clear top performers all wore one? Worth sitting with that question.

The legal patchwork (and why it’s inadequate)

Regulators are scrambling to catch up, and the picture is uneven at best. 🌍

Chile made history in 2021 when its Senate unanimously approved a constitutional amendment to protect brain rights — “neurorights” — becoming the world’s first country to give personal brain data the same status as an organ, so it cannot be bought, sold, trafficked, or manipulated. This wasn’t just symbolic. In August 2023, Chile’s Supreme Court issued a unanimous decision ordering Emotiv to erase the brain data it had collected on a former Chilean senator, in a landmark ruling for neuroprivacy.

In Europe, a 2024 paper in Frontiers in Human Dynamics analyzed how the GDPR and the EU Artificial Intelligence Act apply to workplace neural monitoring. The EU AI Act explicitly prohibits AI systems that deploy subliminal techniques beyond a person’s consciousness or purposefully manipulative techniques. That matters enormously, but the authors found that current regulation still doesn’t fully address the unique nature of neural data.

UNESCO announced global neurotechnology standards in November 2025, introducing a framework explicitly cautioning against using neurotechnology in workplaces for non-therapeutic purposes such as employee monitoring, productivity scoring, or behavioral prediction. UNESCO’s position is clear: brainwave data is a special category that demands special protection.

The regulatory picture, country by country:

• Chile: Constitutional protection for neurorights ✅

• European Union: GDPR + AI Act provide partial coverage; neural data needs explicit handling

• Australia: Current privacy laws contain no provisions specifically protecting employee data generated from neurotechnology — a gap researchers have called urgent to fix

• United States: No federal neurodata law; some state-level moves, but nothing comprehensive

• Mexico and Brazil: Pending constitutional bills following Chile’s lead, with lawmakers actively in discussion as of early 2024

The honest read is that legal protection is fragmentary, enforcement is rare, and the technology is moving faster than any government body is moving to contain it. The industry knows this, and some are counting on it.

Where this is going — and what we should demand

Let’s not pretend this technology is going away. It’s not. The question is whether it develops with workers’ interests in mind, or in spite of them. 🔬⚡

Farahany argues that existing rights — privacy, freedom of thought, and the collective right to self-determination — can and must be updated and interpreted to include cognitive liberty. Human rights law is meant to evolve over time. That’s not a radical position. It’s a reasonable one, backed by the same logic that extended privacy rights to digital communications and biometric data.

There are legitimate, even compelling applications of workplace neurotech — especially in high-stakes safety environments where fatigue genuinely kills people. A long-haul truck driver wearing a SmartCap EEG device that alerts them before they fall asleep at the wheel is meaningfully different from a call center worker whose stress levels are monitored to optimize script delivery. The technology doesn’t determine the ethics; the use does.

A minimally acceptable framework for any responsible deployment would include:

• Genuine informed consent — not a checkbox buried in an employment contract, but a real choice with real alternatives

• Worker access to their own neural data, in full

• Independent oversight of how data is stored, interpreted, and shared

• Hard prohibitions on using neural data in hiring, firing, or promotion decisions

• Time-limited retention — brainwave patterns are not fingerprints; they shouldn’t live forever in a corporate database

What’s missing from this conversation, more than anything, is workers themselves. The pilots and product announcements and ethics papers are largely produced by companies, researchers, and policymakers. The people who’d actually be wearing these devices tend to get consulted last, if at all.

UNESCO’s framework puts it plainly: neural data is uniquely personal. Unlike a fingerprint, it can reveal thoughts, emotions, or cognitive states that individuals never intended to share.

So here’s the question worth pressing on legislators, on HR departments, on every employer who thinks this technology sounds efficient: if you wouldn’t consent to having your brain monitored at work, why would you ask someone else to? And if you would consent — what would need to be true for that consent to be genuinely free, rather than just economically coerced?

The answer to that question probably tells you everything about the kind of workplace — and the kind of society — we’re actually building. For more on the brain-tech frontier, check out 6 signals that neurotech is reaching a tipping point and the brain signals neurotech is already decoding — because the infrastructure for this future is already being assembled, one EEG channel at a time.

Picture two people sitting in separate rooms, miles apart, with no phones, no keyboards, no shared language. One thinks a word. The other receives it — not as a sound or an image, but as a flicker of sensation delivered directly to their visual cortex by a precisely aimed magnetic pulse. This happened in a lab. In 2014. And almost nobody talked about it for a decade.

That’s the story of brain-to-brain communication in a nutshell: astonishing progress, baffling obscurity, and a media cycle that either ignores it entirely or hyperventilates about telepathic cyborgs. Neither response is useful. What’s actually happening is weirder, more interesting, and more consequential than either camp suggests — and 2025 is shaping up to be a genuinely significant year for the field.

How this whole thing actually works

Let’s be precise, because the terminology gets slippery fast. “Brain-to-brain communication” doesn’t mean two people share a mystical mental connection. Technically, what researchers have built is a chain of technology: a brain-computer interface (BCI) reads neural signals from a sender, converts them into data, transmits that data, and then a computer-brain interface (CBI) delivers it to a receiver’s brain through some form of stimulation. The human brain isn’t directly touching another human brain. There’s a lot of silicon in between.

The signal chain looks roughly like this:

• Sender wears an EEG cap or has electrodes in their motor cortex

• Their brain signals are decoded in real time by an algorithm

• The decoded “message” (typically a binary yes/no decision) transmits over the internet

• A transcranial magnetic stimulation (TMS) device fires at the receiver’s occipital cortex

• The receiver perceives a phosphene — a flash of light — that carries the encoded information

It’s elegant in the way a very long game of telephone is elegant. And the accuracy, so far, is modest. Five groups of three subjects tested the BrainNet system — the first multi-person non-invasive brain-to-brain interface — and achieved an average task accuracy of about 81%. That’s impressive for a first demonstration. It’s also a far cry from the kind of rich, nuanced communication you’d want before, say, putting this technology in a hospital.

What makes BrainNet notable is the scale. Developed at the University of Washington, the system used EEG to record brain signals and TMS to deliver information, letting three subjects collaborate on a Tetris-like task through direct brain-to-brain communication alone. Two senders decided whether to rotate a falling block; the receiver, who couldn’t see the screen, received their decisions directly via brain stimulation and acted on them. It’s Tetris. But it’s also the first working multi-person neural social network, and the jump from three brains to thirty is probably less distance than it looks. 🧠

Where Neuralink fits — and where it doesn’t

Here’s a thing that trips people up: Neuralink is not currently building a brain-to-brain communication system. What it’s building — and what it’s getting remarkably good at — is the crucial first half of that chain: reading the brain with unprecedented precision. ⚡

In February 2026, Neuralink announced 21 participants enrolled in its Telepathy program, up from the single subject who made headlines in 2024. One early user named Noland uses the implant to study languages, solve math problems, and write by controlling computers entirely through neural signals. Another participant, Brad — living with ALS and unable to speak — uses the implant to communicate outdoors, something impossible with conventional eye-tracking systems that require controlled lighting.

That’s not telepathy. But it’s a necessary precursor to it. Here’s why: any future brain-to-brain system needs two things to work at scale.

• High-quality signal reading on the sender side (Neuralink’s current focus)

• Precise, comfortable brain stimulation on the receiver side (still a major bottleneck)

Neuralink has made the first part dramatically better. Its device contains electrodes so thin and fragile they must be stitched into the brain by a specialized robot, and the first participant, 29-year-old quadriplegic Noland Arbaugh, reported being able to control a computer cursor and play games using only his thoughts, calling the device “life-changing.”

The company’s own long-term vision, which Elon Musk has described as “consensual telepathy,” involves sharing information between brains directly, enabling instantaneous, wordless communication — with a future “telepathic internet” that could make keyboards and even speech feel outdated. I think that timeline is very optimistic. But the direction is real. 🔬

Meanwhile, Synchron — the company backed by Bill Gates and Jeff Bezos — is taking a less invasive route. Synchron’s device doesn’t penetrate the cortex at all; founder Tom Oxley has argued that “the brain doesn’t really like having needles put into it,” and the company’s stent-based approach has already been implanted in humans. Less signal resolution, but far less surgical risk. The BCI field isn’t converging on a single design. It’s running multiple experiments in parallel, which is probably the right call when nobody is sure what the right answer looks like yet.

The gap between “binary flash” and “sharing a memory”

Here’s where I want to pump the brakes a little, because the gap between current science and science-fiction brain-to-brain communication is enormous — and worth being honest about. 🧬

The most sophisticated demonstrations to date involve transmitting a single bit of information. One flash or no flash. Rotate or don’t. Yes or no. That’s a long, long way from what most people imagine when they hear “brain-to-brain communication.” Sharing a memory, transmitting an emotion, sending a mental image — these require a completely different level of signal fidelity that current technology simply doesn’t have.

The core bottlenecks are:

• Bandwidth: EEG reads from tens or hundreds of neurons at once; the human brain has roughly 86 billion. You’re getting a very blurry picture.

• Decoding: Even with perfect signal capture, we still don’t know enough about how the brain encodes complex thoughts to reliably reconstruct them.

• Stimulation precision: TMS can trigger a flash of light, but it can’t currently write a sentence into your visual cortex.

• Individual variation: Brain activity patterns differ significantly between people, which makes building universal decoders genuinely hard.

Even recent advances in speech decoding — where researchers using implanted sensors achieved accuracy as high as 97.5% in decoding attempted speech in people with ALS — involved decoding motor patterns for speech production, not abstract thought. That distinction matters enormously. Decoding the brain’s instructions to your vocal cords is a much simpler problem than decoding what you’re thinking about. Anyone who tells you we’re close to the latter is either confused or selling something.

What I find genuinely exciting about this moment, though, is how fast speech decoding has improved. If we go from blinking Morse code to 62 words per minute via neural implants (which is where ALS patients are now, per MIT Technology Review), the next decade of compound progress starts to look interesting in a different way. What’s your intuition — is the bottleneck hardware, or is it our fundamental understanding of neural coding?

The ethics conversation nobody is having seriously enough

This is where I’ll be direct: the governance of this technology is moving nowhere near as fast as the technology itself. And that’s a problem we’ll regret. 🌍

In November 2025, UNESCO adopted the Recommendation on the Ethics of Neurotechnology, articulating a normative framework around brain-computer interfaces that emphasizes human dignity, freedom of thought, mental privacy, and autonomy. It calls on states to adopt measures preventing harmful uses, including coercive control, unlawful surveillance, or manipulation. This is real progress. A UNESCO Recommendation is also non-binding, which means it has roughly the legal force of a strongly-worded suggestion.

Chile went further: it became the first country in the world to amend its constitution to explicitly protect “neurorights,” enshrining mental privacy and integrity as fundamental rights. It’s a remarkable move, and also a reminder that every other country has not done this.

The specific concerns with brain-to-brain interfaces go beyond standard BCI data privacy worries. Oxford University philosophers Hazem Zohny and Julian Savulescu identify what might be the most profound issue: linking two minds raises entirely new questions about autonomy, identity, and the delineation of patient interests — challenges that amplify existing healthcare ethics tensions without established frameworks to address them.

Think about what that means concretely:

• If information is transmitted directly to your brain and you act on it, was that action yours?

• If a brain-to-brain link is hacked, what exactly gets stolen?

• If two people share neural states regularly, where does one person’s identity end and another’s begin?

Because brain-to-brain transmissions can travel over the internet, one could theoretically “hack” another’s neural device — researchers have already demonstrated this kind of attack on heart pacemakers, and the principle applies. That’s not science fiction. That’s a security architecture problem waiting for regulators to notice it exists.

Nita Farahany at Duke University, author of The Battle for Your Brain, has argued that mental privacy needs to be treated as a fundamental right now, before the technology reaches scale. I think she’s right. Waiting until brain-to-brain links are commercially available to figure out the legal framework is like drafting seatbelt laws after the highways are full. The time to think hard about this is while the technology is still clunky and limited — which is exactly where we are.

What comes next, realistically

The realistic near-term trajectory for brain-to-brain communication is probably not dramatic public demonstrations. It’s incremental work happening in a few adjacent directions simultaneously. 🚀

Academic labs are continuing to refine non-invasive EEG-to-TMS pipelines, trying to push accuracy and bandwidth higher without requiring surgery. Neuralink and Synchron are racing to improve invasive BCIs primarily for therapeutic use, but the signal-reading infrastructure they’re building is dual-use: better at reading brains for medical purposes, but also potentially applicable to sending information between brains later. AI is starting to play a major role in decoding, since the pattern-matching that large neural networks excel at turns out to be very useful for interpreting the noisy, idiosyncratic signals of individual brains.

Neuralink is actively working on closed-loop systems where the brain not only sends commands but also receives feedback — mimicking natural bidirectional communication. The company also plans to expand clinical trials beyond the U.S. to Canada, the UK, Germany, and the UAE. Closed-loop bidirectional systems are the actual technical prerequisite for anything resembling real brain-to-brain communication at scale. Right now, most systems only go one direction.

The field also has serious competition from non-invasive approaches. Wearable EEG is getting better every year. Functional near-infrared spectroscopy (fNIRS) is emerging as a complementary tool. And AI decoding is dramatically lowering the bar for how clean a signal needs to be to extract useful information from it. You might not need to drill into a skull to build a functional brain-to-brain interface in 2035. That’s a legitimately open question.

If you’ve made it this far and you’re working in neurotech, BCI research, or even just thinking seriously about cognitive futures — what’s your honest assessment of the decade timeline? The binary-flash-to-shared-experience gap is the central unsolved problem. Where does the breakthrough come from?

The short, unsatisfying answer is: we don’t know. But for the first time in history, we have 21 people walking around with working brain implants, researchers who’ve demonstrated multi-brain collaborative networks, a budding international regulatory conversation, and enough published science to stop treating this as speculation. Brain-to-brain communication is real, limited, and accelerating. The question isn’t if anymore. It’s how fast — and who gets to decide how it’s used.

For decades, Alzheimer’s research felt like a long, slow defeat. The disease would take a person’s memories, then their personality, then their independence — and the best medicine could do was hand out drugs that delayed the inevitable by a few months. That era isn’t over, but something has genuinely shifted. A combination of new pharmacology and, more interesting to us here at NeurotechMag, a surge of neurotechnology-driven approaches are producing results that would have sounded like science fiction ten years ago. Mice navigating mazes they couldn’t previously solve. Hippocampal atrophy halting in its tracks. Memory circuitry being switched back on. 🧠

None of this is a cure yet — let’s be clear about that from the start. But the pipeline is fuller, more diverse, and more mechanistically credible than it has ever been. And the shift in thinking, from “slow the decline” to “restore function,” is real. Here’s what’s actually happening.

The drug front: clearing the amyloid mess

The most talked-about development in Alzheimer’s pharmacology over the last two years is the arrival of anti-amyloid immunotherapy as a real, FDA-approved treatment category. Lecanemab (brand name Leqembi) and donanemab (Kisunla) received FDA approval in 2023 and 2024 respectively, and both have been shown to clear the majority of beta-amyloid plaque deposits from the brain over 12 to 18 months of IV infusion treatment, slowing cognitive decline by roughly 30%. That sounds modest. It isn’t. For early-stage patients, 30% slower decline is the difference between recognizing your grandchildren for an extra year or not.

In the pivotal TRAILBLAZER-ALZ 2 trial, donanemab slowed cognitive decline by 35% in early-stage patients, with some subgroups showing a 39% lower risk of disease progression. Eli Lilly also made donanemab the first amyloid therapy where treatment discontinuation is supported by evidence once the plaques are cleared — a meaningful practical win, since it potentially reduces both cost and the burden of repeated hospital infusions.

The next generation isn’t standing still either. Key developments include:

• Trontinemab, which uses a “Brainshuttle” technology to push higher concentrations of antibody across the blood-brain barrier than previous drugs manage

• Blarcamesine (Anavex’s oral candidate), which activates the sigma-1 receptor to drive neurons to clear plaques themselves — currently in Phase 2/3 trials

• ALZ-801, targeting the upstream formation of toxic amyloid rather than the plaques themselves

• NU-9, a small molecule from Northwestern University that clears toxic amyloid beta oligomers in hippocampal brain cells, the region most critical for learning and memory 🔬

UC San Francisco’s Adam Boxer compares where Alzheimer’s medication is today to the state of HIV drugs in the 1980s — early, imperfect, and full of side effects, but the beginning of a trajectory that eventually produced highly effective treatments. That framing is exactly right, and it’s a useful antidote to both overclaiming and despair.

Does the current approval of lecanemab and donanemab excite you, or do you think the modest effect size means the field is still fundamentally stuck? Drop your take in the comments.

The gamma wave gambit

Here’s where neurotechnology gets genuinely strange and wonderful. 💡 The MIT Picower Institute has spent years investigating a striking observation: Alzheimer’s patients show a measurable deficit in 40 Hz gamma oscillations, the fast rhythmic brain activity associated with memory encoding and retrieval. The question was whether you could just... put those oscillations back in, non-invasively, using lights and sound.

Turns out, you might be able to. A non-invasive therapy called GENUS (Gamma Entrainment Using Sensory stimulation), which uses 40 Hz audiovisual stimulation, has shown memory benefits in both Alzheimer’s mouse models and patients with mild probable Alzheimer’s disease. The proposed mechanisms are multiple:

• Reduced amyloid and tau load, primarily by activating microglia (the brain’s immune cleanup crew)

• Enhanced brain drainage and clearance of waste proteins

• Restoration of neural network synchronization in memory-critical regions

• Improved long-term potentiation — essentially, better capacity for the brain to form new memories ⚡

An open-label extension study published in Alzheimer’s & Dementia in 2025 evaluated the long-term effects of daily 40 Hz audiovisual stimulation on cognition and biomarkers in patients with mild Alzheimer’s disease. The MIT group is now running a prevention trial at Massachusetts General Hospital, recruiting adults aged 55+ with a family history of Alzheimer’s, using the device for 60 minutes a day at home for 12 months.

There are honest scientific debates here worth acknowledging. Some researchers question whether true gamma oscillations are even being entrained by sensory stimulation, and note limited propagation of the effect beyond the visual cortex, with limited engagement in key regions like hippocampal CA1. That’s a real concern. But the clinical signals are intriguing enough that several large trials are proceeding. Cognito Therapeutics, whose Spectris device uses a similar flicker approach, presented data at AAIC 2025 showing neuroprotective potential, and Sinaptica Therapeutics reported that personalized, non-invasive brain stimulation slowed cognitive decline by 44 percent in a Phase 2 trial for mild-to-moderate Alzheimer’s.

That number — 44 percent — deserves a moment. If that holds up in larger trials, it’s not a footnote. It’s a headline.

Deep brain stimulation: the invasive bet paying off slowly

If flickering lights are the gentlest intervention in this space, deep brain stimulation (DBS) is the most aggressive. It involves surgically implanting electrodes into specific brain structures and delivering continuous or patterned electrical stimulation. It’s already an established therapy for Parkinson’s disease and treatment-resistant depression. Alzheimer’s is a much harder target, but the early data is compelling enough that trials keep advancing. 🔬

The main target sites researchers have focused on include:

• The fornix, the primary output pathway connecting the hippocampus to memory-related circuits

• The nucleus basalis of Meynert (NBM), a cholinergic structure whose degeneration is one of the earliest events in Alzheimer’s pathology

• The entorhinal cortex, the gateway through which sensory information enters the hippocampus

In the ADvance trial examining fornix DBS, patients who received the implant showed stable hippocampal volumes at the 12-month mark — a striking finding given that the typical Alzheimer’s comparison group loses roughly 5% of hippocampal volume per year. No atrophy. In a disease defined by tissue loss, that counts as something.

At the Medical College of Georgia, neuroscientist David Blake started human trials in January 2026 targeting the nucleus basalis of Meynert. His team’s protocol involves 50 minutes of DBS per day, delivered remotely by the patient or caregiver, using a 10-seconds-on, 40-seconds-off interval pattern Blake describes as “a little interval workout for the brain.” In animal studies, every single animal showed cognitive improvement without fail. That kind of result in a mouse or primate model doesn’t guarantee human translation, but it demands follow-through.

A 2025 clinical study in the journal CNS Neuroscience & Therapeutics compared fornix-DBS and NBM-DBS in patients with severe Alzheimer’s and found both improved cognitive function and quality of life, with NBM-DBS showing particular advantages in neuropsychiatric symptom management.

The question nobody can fully answer yet is long-term durability. Short-term cognitive enhancement is appearing across multiple DBS targets. Whether that enhancement holds at two years — and prevents the slide into total dependence — is what the current generation of trials is trying to find out.

The molecular wildcards: GABA receptors and nasal sprays

Not everything happening at the frontier requires electrodes or infusion suites. Some of the most intriguing work is molecular, and a couple of approaches are genuinely surprising in their simplicity. 💊

Researchers at the Centre for Addiction and Mental Health (CAMH) in Toronto, led by Etienne Sibille, identified a compound that targets alpha-5 GABA-A receptors — a subtype of the brain’s primary inhibitory receptors that regulate the balance between neural excitation and suppression. In Alzheimer’s, this balance tips badly wrong. The resulting spinoff company, Damona Pharmaceuticals, received FDA clearance for human clinical trials and planned to begin Phase 1 enrollment in early 2025. The mechanism is genuinely different from the amyloid-focused mainstream, which matters: one target being wrong doesn’t doom the other.

Meanwhile, the University of Texas Medical Branch published work in Science Translational Medicine on a different delivery system entirely. A nasal spray treatment showed promising results in clearing harmful tau protein buildup and improving cognitive functions in aged mice with neurodegenerative disease, with lead author Dr. Rakez Kayed noting that the approach “opens new avenues for non-invasive delivery of tau therapeutic antibodies directly to the brain.”

Then there’s the UCLA finding: a small molecule identified by Istvan Mody’s lab. When given to mice with Alzheimer’s disease, the treated animals — who previously couldn’t remember the route out of a maze — performed almost as well as healthy mice. Mody’s summary: “We may be able to restore cognitive function. That’s the ultimate hope.”

These aren’t the same mechanism, which is the point. Alzheimer’s isn’t one problem. It’s a cascade of failures — amyloid buildup, tau tangles, neuroinflammation, synaptic loss, oscillatory disruption, cholinergic degeneration — happening in sequence and in parallel. No single drug or device is likely to beat it. A combination will.

The bigger shift: diagnosis before damage

One thing rarely mentioned in mainstream Alzheimer’s coverage is that all of these treatments — drugs, DBS, gamma entrainment, molecular therapies — work far better the earlier you intervene. And the diagnostic picture has changed dramatically. 🧬

The FDA cleared the first blood test for diagnosing Alzheimer’s disease in May 2025, and the National Institute on Aging together with the Alzheimer’s Association released revised diagnostic criteria in 2024, formally defining the disease by its biology rather than its clinical symptoms. In practical terms: you no longer need a PET scan or a painful lumbar puncture to establish that Alzheimer’s pathology is present in the brain. A blood draw can do it.

This matters enormously for neurotech. Brain stimulation approaches like DBS and GENUS need neurons to work with. Anti-amyloid drugs need plaques that haven’t yet killed the circuitry downstream. The Lancet Commission’s 2024 updated report outlined 14 modifiable risk factors — including hearing loss, high LDL cholesterol, physical inactivity, and social isolation — that together could theoretically reduce global dementia cases by up to 45% if addressed systematically. The best neurotech in the world won’t save a brain that waited too long.

The opportunity, right now, is combining these tools: catch the disease early with a blood test, slow the amyloid cascade with lecanemab or donanemab, restore oscillatory function with non-invasive gamma entrainment, and use DBS or targeted molecular therapies in patients where the disease has already progressed further. As of early 2026, nearly 200 clinical trials are underway assessing more than 150 novel drugs, with an increasingly diverse range of biological targets well beyond amyloid.

We’ve covered the broader neurotech acceleration in 6 Signals That Neurotech Is Reaching a Tipping Point, and the Alzheimer’s story is one of the most vivid illustrations: investment, regulatory momentum, biological insight, and device innovation all moving in the same direction at the same time.

The honest question now isn’t whether the field is making progress. It clearly is. The question is whether the pace of clinical translation — notoriously slow, notoriously expensive — can keep up with the 55 million people worldwide currently living with dementia. What do you think needs to happen to close that gap?

Electric brain stimulation has a marketing problem. The pitch sounds almost too good: strap a headset on your skull, run a gentle current through your prefrontal cortex, and watch your cognitive performance climb. Tech forums are full of testimonials. Biohackers post protocols with missionary zeal. And consumer devices now sell for a few hundred dollars on the internet, no prescription required.

But here’s the thing — the science underneath all that enthusiasm is simultaneously more fascinating and more sobering than the boosters admit. Researchers genuinely can alter how neurons fire using nothing but carefully placed electrodes and milliamps of current. The effects are real. The disagreements are about which effects, how large, and whether any of it translates to the thing most people actually care about: getting smarter.

Let’s take a serious look at what the research actually shows, where the genuine promise lives, and why “I zapped my brain for 30 days and my IQ went up” might not mean what you think.

What brain stimulation actually does

Before we can talk about boosting intelligence, it helps to understand what these devices are physically doing to your neurons. The two most studied techniques are transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS), and they work through different mechanisms.

tDCS sends a weak, steady electrical current — typically between 1 and 2 milliamps — through electrodes placed on your scalp. That current flows between an anode (positive electrode) and a cathode (negative electrode), and the area of cortex under the anode tends to become more excitable while the area under the cathode becomes less so. Think of it as turning a regional dimmer switch slightly up or down. Nothing dramatic happens electrically — you might feel a mild tingling or warmth. But at the cellular level, anodal stimulation nudges neurons closer to their firing threshold, which appears to enhance certain kinds of information processing in the targeted region. 🔬

• tDCS uses a continuous low current, is cheap and portable, and requires no special expertise to operate

• TMS uses magnetic pulses to induce brief electrical currents in deeper cortical tissue, requires clinical equipment, and can produce effects that last significantly longer

• tACS (transcranial alternating current stimulation) is the newcomer — it oscillates at specific frequencies to entrain existing brain rhythms rather than just raising or lowering neural excitability

• HD-tDCS (high-definition tDCS) uses smaller, more precise electrode configurations to target specific brain regions with less spread

The reason researchers care so much about the dorsolateral prefrontal cortex (DLPFC) is that this region sits at the intersection of working memory, executive control, and fluid reasoning. If you’re going to nudge a region in hopes of smarter thinking, the DLPFC is the obvious starting point. Does it work? That’s where things get complicated. 🧬

What the evidence actually shows — the good news first

Let’s start where the science is clearest, because there is something real here. A 2021 meta-analysis of 82 randomized controlled trials including nearly 2,800 participants found that both TMS and tDCS produced small but statistically significant improvements in working memory (effect size around 0.17 for both techniques) and that tDCS additionally improved attention and vigilance. These effects held across different types of brain disorders — depression, schizophrenia, Parkinson’s disease, stroke recovery.

That’s not nothing. A working memory boost, even a small one, has genuine downstream effects on learning, reasoning, and task performance. And in populations with compromised cognition, “small” improvements can mean the difference between functional independence and struggling to manage daily life.

In older adults specifically, the results look promising:

• Anodal tDCS over the DLPFC produced significant gains in attention, information processing speed, and short-term memory in a University of Alberta study of adults between 65 and 86 years old

• A systematic review of randomized controlled trials published between 2015 and 2025 specifically examining healthy older adults found consistent evidence for cognitive benefit, with results most pronounced at stimulation intensities of 1.5–2 mA over 20-minute sessions

• Research from a 2024 Frontiers in Psychology editorial synthesis found that older individuals with higher education levels showed especially strong responses to tDCS, while younger people responded better to tACS

The tACS story is arguably more interesting than tDCS for cognitive enhancement specifically. ⚡ Rather than just pushing neural excitability up or down, tACS entrains the brain’s own oscillatory rhythms. Research published in PLOS ONE found that theta-frequency tACS over the left parietal cortex produced measurable increases in fluid intelligence performance — particularly on difficult reasoning items. A separate line of research showed that gamma-frequency tACS (40 Hz) over the left prefrontal cortex shortened the time participants needed to solve abstract reasoning problems.

The mechanism here is genuinely elegant: fluid intelligence appears to rely on efficient communication between the parietal and prefrontal cortices, and synchronizing oscillatory activity in those regions seems to make the neural “conversation” more efficient. What does that feel like? Probably something like finding yourself solving hard problems slightly more fluidly — not a sudden burst of genius, but a reduced friction. Have you ever noticed that some days your thinking just flows better? tACS might be artificially inducing that state.

The inconvenient results

Here’s where I have to disappoint the biohackers a little. If you’re hoping to sit down with a tDCS headset and walk away with a meaningfully higher IQ score, the evidence should give you serious pause. 💡

The most pointed study on this comes from Flavio Frohlich’s lab at UNC School of Medicine. In a double-blind, randomized, sham-controlled study published in Behavioural Brain Research, 40 healthy adults took the WAIS-IV — a gold-standard, comprehensive IQ test — before and after either real tDCS over the frontal cortex or fake stimulation. The results were the opposite of what the boosters would predict:

• The sham group’s IQ scores improved by about 10 points (largely due to practice effects)

• The tDCS group’s scores improved by only about 6 points on average

• Specifically, tDCS reduced improvement on the perceptual reasoning subtest

Frohlich’s interpretation is worth sitting with: “It means that some of the most sophisticated things the brain can do, in terms of cognition, can’t necessarily be altered with just a constant electric current.” The prefrontal cortex already handles complex cognition through intricate patterns of oscillating neural activity. Flooding it with a simple direct current may actually interfere with those patterns rather than enhance them. 🔬

This aligns with a key insight from the broader tACS research: the brain is not a static system you can nudge in a single direction. It communicates in rhythms. Crude DC stimulation can raise or lower excitability, but it doesn’t care about the timing. That’s probably why the effect profile for tDCS on IQ looks inconsistent, domain-specific, and sometimes backwards.

Other complicating factors the field is actively wrestling with:

• Inter-individual variability is enormous — skull thickness, brain anatomy, baseline cognitive state, and even genetics (particularly BDNF and COMT gene variants) all influence how strongly and in what direction a person responds to stimulation

• The replication crisis has touched this field too — researchers at the Frontiers in Human Neuroscience noted in a 2023 editorial that reliability and reproducibility remain significant challenges in brain stimulation research, particularly for non-invasive techniques

• Timing effects are underappreciated — whether tDCS is applied before, during, or after a cognitive task changes the direction of the effect on learning consolidation

The consumer device question

The commercial application of tDCS is moving much faster than the science. In late 2025, Flow Neuroscience became the first company to receive FDA approval for an at-home tDCS device, though the approval was specifically for major depressive disorder, not cognitive enhancement. The evidence for that particular application is actually reasonably solid — a 2024 phase 2 trial involving 174 participants showed participants using the headset for 30-minute sessions over 10 weeks were roughly twice as likely to experience depression remission compared to sham controls. 💊

Flow subsequently acquired Halo Neuroscience, which sells what it describes as identical hardware as a wellness device — available without a prescription. This creates a genuinely strange regulatory situation: you can buy the same hardware marketed as consumer wellness, or get a near-identical device by prescription for depression treatment. The FDA’s framing of the benefit as “modest, but sufficient to outweigh probable risk” tells you something about the magnitude we’re discussing.

If you’re considering a consumer tDCS device for cognitive enhancement specifically, here’s an honest framework:

• The evidence for mood, sleep, and attention benefits in general populations is more encouraging than the evidence for IQ-type gains

• Effects are likely to be most noticeable if you have some baseline deficit in the domain you’re targeting — healthy, high-performing people may see smaller effects or none at all

• Combining tDCS with simultaneous cognitive training appears to produce larger effects than either alone, per research on neuroplasticity-based enhancement

• Safety at standard consumer currents (1–2 mA, 20–30 minute sessions) appears solid — skin redness and mild tingling are the most common complaints, with no evidence of lasting harm in healthy adults at standard doses

Robert Reinhart, an associate professor at Boston University who studies brain stimulation, has called the overall evidence base for tDCS “mixed” — even as he acknowledges that the FDA approval for depression treatment is a meaningful moment for the field. That’s probably the right calibration. Not hype, not dismissal.

Where the science is headed

The most exciting work in cognitive enhancement via brain stimulation is moving toward personalized, oscillation-targeted protocols — the stuff tACS and closed-loop stimulation make possible. ⚡

Instead of applying the same protocol to everyone and hoping for the best, researchers are increasingly measuring a person’s individual EEG rhythms and tailoring the stimulation frequency and timing to match. A 2025 clinical trial currently recruiting participants (NCT07095218) is combining gamma tACS with EEG measurement of theta-gamma coupling — one of the most theoretically grounded approaches to intelligence enhancement yet attempted.

The trajectory of the field looks something like this:

• 2000–2015: tDCS boom, enthusiasm, early mixed results

• 2015–2022: Replication failures, sobering meta-analyses, recognition that one-size-fits-all protocols are the wrong approach

• 2022–present: Personalized protocols, closed-loop systems, tACS entrainment, combination approaches with cognitive training and exercise

• Near future: FDA-regulated cognitive enhancement devices? Possibly — though the regulatory pathway for enhancing healthy brains rather than treating disease is genuinely uncharted territory

The honest answer to the question in this article’s title is: brain stimulation probably can’t boost your IQ in the headline-grabbing, 10-points-permanently sense. What it may do — particularly with tACS and well-designed personalized protocols — is temporarily improve specific cognitive processes like working memory, attention, and fluid reasoning. In some populations, especially older adults or those with depression, those effects could be clinically meaningful. In healthy young adults already performing near their ceiling, the effects might be negligible or even counterproductive. 🧬

The brain isn’t a muscle you can simply shock into strength. It’s closer to an orchestra — and the question isn’t whether to turn up the volume, but whether you can improve the timing.

What would actually change your mind about brain stimulation — a large, preregistered trial showing IQ gains in healthy adults, or better evidence that the effects we already see in clinical populations generalize beyond the lab?

If you’ve followed neurotech for more than five minutes, you’ve probably felt the whiplash. One week, Elon Musk is suggesting his brain chip will let you “save and replay memories.” The next, researchers quietly publish a study showing a 47-year-old woman who hadn’t spoken in 18 years just decoded speech at 47.5 words per minute using a cortical implant. The Musk quote gets three million impressions. The actual science gets a press release on a government website.

That gap — between what’s being sold and what’s being built — is the most important thing to understand about neurotech right now. This field is simultaneously more boring and more astonishing than the headlines suggest. Less “merge with AI by Thursday,” more “a paralyzed man can now text his family without using his hands.” Which is, if you think about it for a second, genuinely extraordinary.

The question worth asking isn’t “is this hype?” It’s “where exactly does the hype end and the real stuff begin?” The line shifts almost monthly. So let’s draw it.

What’s actually working right now

Start with the clearest proof point. An NIH-funded team led by Dr. Edward F. Chang at UCSF and Dr. Gopala Anumanchipalli at UC Berkeley implanted an array of electrodes over the speech-encoding area of a 47-year-old woman’s brain. She had been unable to speak or produce any vocal sounds for 18 years following a stroke. Their system, published in Nature Neuroscience in March 2025, decoded words and synthesized speech in increments of 80 milliseconds — less than a quarter of a second — and achieved a more than 99% success rate. For a 50-word vocabulary, it reached 90.9 words per minute. 🧠

That’s faster than many people type. And it’s not a one-off.

Synchron’s Stentrode is the other device that deserves real attention right now, partly because it reaches the brain without requiring a single drill to the skull. The Stentrode is delivered via catheter through the jugular vein and lodged in the motor cortex’s draining vein, where it records brain signals through the vessel wall. In Synchron’s COMMAND trial — the first FDA-approved investigational device exemption trial of a permanently implanted BCI — all six patients with severe bilateral upper-limb paralysis successfully met the primary endpoint: no device-related serious adverse events such as death or permanent increased disability.

The real-world implications are already showing up. Synchron recently demonstrated its BCI controlling Apple Vision Pro using only brain signals. That’s not a lab demo with a wired rack of equipment behind it. That’s a paralyzed person using a consumer device with their mind. 🔬

The things that are working right now:

• Motor BCIs that let paralyzed patients control cursors, type, and navigate digital interfaces

• Speech neuroprostheses decoding silent attempted speech into real-time audio

• Endovascular implants (Synchron’s Stentrode) that avoid open-brain surgery entirely

• Deep brain stimulation for movement disorders, already FDA-cleared and in use for decades

• EEG-based neurofeedback for epilepsy monitoring, ADHD, and PTSD symptom management

None of these are science fiction. All are in human trials or cleared for use.

Where Neuralink actually stands

Let’s be precise about this, because imprecision has cost the field credibility. Neuralink is not a fraud. It’s also not what Elon Musk describes at his presentations. Two years into actual human trials, the company has successfully demonstrated brain-to-cursor control in human patients. What Neuralink has achieved is essentially a very expensive assistive mouse.

That framing stings a little, but it’s fair. The brain doesn’t think in binary code or discrete commands. Translating the messy, analog output of neural activity into precise digital signals requires massive computational interpretation, and that interpretation gets exponentially harder as you move beyond simple motor commands. The leap from cursor control to “downloading knowledge” isn’t an engineering challenge. It’s a categorical mismatch between the promise and what neurons actually do. ⚡

Durability is a real technical problem too. Utah arrays — the bed-of-nails style electrode implants used in many research BCIs — often lose signal from over 60% of their electrodes within one year, as scar tissue forms around the implant and muffles the signal. This isn’t a Neuralink-specific problem. It’s a fundamental biological fact: the brain’s immune system treats implanted electrodes as foreign invaders, because they are.

What Neuralink has contributed:

• Proving the surgical robot can implant thousands of fine electrodes with precision

• Demonstrating that patients with severe paralysis can use the system safely

• Pushing the entire BCI field toward higher electrode counts and miniaturization

• Attracting enough capital to fund serious competing research

The problem isn’t the science. It’s the gap between “paralyzed patients can control a cursor” and “you’ll be able to stream music directly into your brain.” Those are not on the same timeline. One exists today. The other may never exist as described.

Have you adjusted your own mental model of where BCI technology sits? If you came in thinking neural lace was five years away, has any of this shifted your expectations?

The signal degradation nobody talks about

Here’s the part that gets glossed over in investor decks. The brain is not a passive substrate for electronics. It’s a dynamic, immunologically active organ that remodels around implants. Any technology claiming long-term viability has to deal with neuroimmunology, not just microfabrication.

Today’s BCIs must be painstakingly trained to each user’s unique neural patterns, and performance can fluctuate daily with fatigue or mood. This is not a software problem you can patch overnight. It means every implanted BCI user is essentially running a custom-trained system that has to be periodically recalibrated. 🔬

The Columbia and Stanford teams published something striking in late 2025: a chip with 65,536 electrodes and 1,024 channels, streaming wirelessly. The lead researcher called it “a fundamentally different way of building BCI devices,” with “technological capabilities that exceed those of competing devices by many orders of magnitude.” That’s a genuine leap in channel count. Whether it translates into proportionally better clinical outcomes is the question that only long trials can answer.

The honest technical picture, broken down:

• Invasive systems have better signal quality but cause scarring and signal loss over time

• Endovascular systems (like the Stentrode) are safer but pick up lower-resolution signals

• Non-invasive EEG is accessible but has latency of 800–1,200 ms and accuracy problems in noisy environments

• Signal decoding is improving fast thanks to AI, but daily recalibration is still often required

• Long-term durability remains the hardest unsolved engineering problem in the whole field

The good news is that AI-powered decoders are genuinely changing what’s possible with the signals that do come through. The UCSF speech neuroprosthesis works partly because modern deep learning can extract meaning from noisy, partial neural signals in ways that would have been impossible five years ago. The hardware is improving, but the software is arguably improving faster.

The consumer market: mostly noise, some signal

This is where the hype concentration is highest. Walk into any tech conference and you’ll see EEG headbands promising to “supercharge your meditation,” focus-tracking earbuds claiming to prevent burnout, and sleep wearables that offer to “decode your brain state.” Most of it deserves healthy skepticism.

“The problem with a lot of consumer EEG tech is that it doesn’t work well or at all,” says Ramses Alcaide, co-founder of Neurable. His company spent a decade and collected data from around 7,000 people to design EEG technology accurate enough to fit inside headphones while retaining meaningful signal quality. That’s a remarkably honest thing for a company selling brain-reading headphones to admit. But it’s also probably true of most of their competitors.

Professor Karl Friston at University College London, one of the world’s most influential neuroscientists, says the best way for a consumer to approach wearable EEGs is by treating them with the same level of reverence as a household thermometer. He’s right. These devices can tell you something real about your brain state — like a thermometer tells you something real about your body — but they’re nowhere near the diagnostic tools their marketing implies. 💡

Some specific things to watch in this space:

• Neurable’s MW75 Neuro headphones, which embed EEG sensors in noise-canceling headphones and have actual signal processing research behind them

• Muse S Athena, which launched in early 2025 combining EEG with fNIRS for a genuinely deeper picture of brain oxygenation during meditation

• NAOX earbuds, a French startup building clinical-grade EEG into true wireless earbuds for longitudinal monitoring of conditions like epilepsy

Consumer neurotech firms now account for 60% of the global neurotechnology industry, outnumbering medical ones since 2018. Since 2010, consumer firms have proliferated more than four-fold. That’s a lot of companies. The signal-to-noise ratio in consumer neurotech is, fittingly, not great.

The thing that does deserve attention: the Centre for Future Generations’ 2025 neurotech market atlas notes that miniaturization and AI are genuinely accelerating integration. EEG sensors are getting small enough to live in earbuds. The question of “when does passive brain monitoring become part of everyday wearables” is not crazy to ask. It’s probably a decade away, not two.

What the next 18 months actually look like

Paradromics received FDA IDE approval for its Connexus system to start the Connect-One early feasibility study, targeting speech restoration and computer control in people with severe paralysis via a high-bandwidth, fully implantable BCI. Unlike cursor control, this trial is designed around speech restoration as a primary endpoint — which means if it succeeds, we’ll have direct evidence of a device designed from the start to give people back their voice. That matters. 🚀

The realistic outlook for the next two years: expansion of endovascular BCIs into post-stroke aphasia and upper-limb amputation, with a focus on reliability rather than bandwidth. Expect two or three new FDA De Novo clearances for communication-focused systems.

What’s not coming in the next 18 months:

• FDA approval of any BCI for general consumer use

• Reliable long-term implants without signal degradation

• Anything resembling “thought uploading” or memory augmentation

• Consumer brain chips that actually work the way the pitch decks describe

What is coming:

• More human trial data from Synchron, Neuralink, Precision Neuroscience, and Paradromics

• Improved AI decoders that extract more from the same electrodes

• Real competition between companies driving faster iteration

• Growing regulatory clarity on what “BCI safety” actually requires long-term

MIT Technology Review called BCIs one of its 10 Breakthrough Technologies of 2025, and research scientist Michelle Patrick-Krueger at the University of Houston characterizes this as “the translation era” — a period of considerable private investment focused on moving BCI from research into clinical practice.

That framing is exactly right. This is a translation era, not a deployment era. The science is outrunning the infrastructure, the regulation, and in some cases the honesty of the people selling it.

The question that keeps me up at night isn’t whether BCIs will eventually work — the UCSF speech results make that essentially certain. It’s whether the companies racing to be first will cut corners on long-term safety data to get there. Because the brain deserves more patience than a quarterly earnings cycle allows.

What would it take for you to actually trust a brain implant enough to consider one?

There’s a quiet revolution happening in psychiatry, and it doesn’t involve a new pill. After decades of treating PTSD and depression with variations of the same handful of drugs, researchers and clinicians are finally doing something different: they’re going directly to the brain. Not metaphorically. Literally. Magnets, electrodes, virtual reality headsets, and neurofeedback rigs are now part of the standard conversation at serious research hospitals and VA centers across the country.

The results are, in many cases, remarkable. And for the millions of people who’ve cycled through antidepressant after antidepressant with little relief, “remarkable” is not a small word.

Up to 30% of people with depression don’t respond adequately to first-line treatments. For PTSD, the picture is grimmer still — the primary pharmaceutical options remain SSRIs and SNRIs, medications that offer only partial relief for a significant subset of patients. That’s not a niche problem. That’s tens of millions of people stuck. What follows is a breakdown of the treatments actually moving the needle right now — not the ones that might work in five years, but the ones that are already changing lives.

TMS: the magnet treatment that went from “fringe” to mainstream

Transcranial magnetic stimulation (TMS) has had a reputation problem. For years, people heard “magnets on your head” and filed it somewhere between “experimental” and “probably a scam.” That reputation is now officially dead. 🧠

A major expert review published in Clinical Neurophysiology in 2025, backed by the National Network of Depression Centers and the International Federation of Clinical Neurophysiology, surveyed nearly 2,400 studies. The conclusion was unambiguous: in real-world settings, up to 83% of patients show improvement, and more than half may achieve full remission. For a treatment with minimal side effects — mostly mild scalp discomfort — that’s a striking track record.

Now consider the logistics problem TMS has always had: six to eight weeks of daily clinic visits. That schedule rules out anyone juggling work, kids, chronic illness, or a car-free existence in a rural county. Researchers at UCLA recently attacked that problem head-on with a “5x5” protocol — five sessions a day, five days in a row. Their study of 175 patients found meaningful symptom relief comparable to the standard schedule, and patients who didn’t respond immediately showed an average 36% drop in depression scores two to four weeks later. The brain, it turns out, sometimes needs a moment to catch up.

Even more compressed: accelerated deep TMS delivered over just six days achieved clinical outcomes comparable to standard multi-week treatment in patients with major depressive disorder, according to two newly published studies in Brain Stimulation. The treatment protocol in that trial — called SWIFT — cut the acute treatment phase from roughly 36 visits to 6 half-day sessions.

Key things to know about TMS right now:

• Theta burst stimulation (iTBS) achieves the same results as traditional TMS but takes only minutes per session

• As of 2024, TMS has FDA clearance for patients as young as 15, expanding its reach beyond adult MDD

• Most major insurance plans cover TMS for treatment-resistant depression

• Serious side effects, like seizures, are extremely rare — lower risk than some common antidepressants

• Researchers are actively exploring its use for PTSD, OCD, and anxiety disorders

One thing that genuinely excites me here: TMS is no longer just for people who’ve exhausted everything else. Some clinicians are starting to consider it earlier in treatment, particularly when medications are contraindicated or refused. That shift in thinking could dramatically change who gets access.

Brain stimulation for PTSD: electricity meets virtual reality 🪖

PTSD is a harder target than depression. The neuroscience is messier — it’s not just a circuit that’s underactive, it’s a whole system that’s misfiring in response to threat memories. But that complexity is exactly where neurotech has found traction. ⚡

Researchers at Brown University’s Warren Alpert Medical School ran a double-blind study with 54 military veterans who had chronic PTSD. The protocol combined virtual reality warzone exposure with transcranial direct current stimulation (tDCS) — a low, painless electrical current targeted at the ventromedial prefrontal cortex, the brain region responsible for safety learning. Participants in the active tDCS group reported superior reductions in PTSD symptom severity at one month, while the VR component produced meaningful benefits for all participants. The combination worked better than either element alone.

Why does this work? A leading theory holds that PTSD impairs the prefrontal cortex’s ability to regulate the amygdala, disrupting the safety learning and memory that healthy brains use to stop being afraid of things that are no longer dangerous. Stimulating that prefrontal region during exposure therapy essentially gives the brain a nudge in the right direction — like helping a jammed lock turn.

Then there’s PRISM, a device from GrayMatters Health that received FDA 510(k) clearance in 2023 and is already available at select clinics. It’s a self-guided, real-time neurofeedback tool that lets patients learn to regulate the specific neural patterns associated with their PTSD symptoms. In a multi-center clinical trial of patients with chronic PTSD, 67% showed clinically significant symptom improvement at three-month follow-up, and 32% achieved remission after 15 sessions. Significant sleep improvements were also documented — notable, since sleep disruption is one of the most debilitating and stubborn features of the disorder.

If you’re curious about how neurotech is reshaping treatment for complex conditions like this, the broader picture is laid out well in How Neurotech Is Quietly Replacing Antidepressants for Some Patients — required reading for anyone tracking where this is heading.

Deep brain stimulation: the most dramatic intervention of all 🔬

For patients who’ve failed everything — multiple medications, TMS, electroconvulsive therapy — deep brain stimulation (DBS) is increasingly on the table. This is not a subtle treatment. It involves implanting electrodes directly into specific brain structures and delivering continuous electrical pulses. It’s neurosurgery. But for the roughly 40% of depression patients who don’t respond to any available treatment, neurosurgery starts sounding a lot more reasonable.

A meta-analysis published in the Journal of Neurosurgery in September 2025 examined 22 clinical trials to compare different DBS targets for treatment-resistant depression. The findings:

• The medial forebrain bundle (MFB) achieved the highest responder rate at 86%

• The subcallosal cingulate gyrus and anterior limb of the internal capsule both showed significant improvements over sham stimulation

• Overall, DBS was consistently more effective than sham stimulation across all analyzed targets

• The MFB’s high success rate is likely tied to its central role in dopamine pathways — the circuits governing motivation and reward

• The highest remission rate observed was 60%, though this varied by target and study

I want to be clear about what those numbers mean in context: these are patients who had already failed multiple other treatments. A 60% remission rate in that population is extraordinary. For comparison, SSRIs achieve full remission in roughly 30-40% of patients who haven’t already failed prior treatments.

DBS is still expensive, still invasive, and still not widely available outside major academic medical centers. But as the evidence base grows and the technology miniaturizes, that’s going to change. What do you think — is the idea of brain-implanted electrodes treating depression something you’d consider if everything else had failed?

The biology of fear, and the drugs trying to rewrite it 💊

Alongside the hardware, there’s a genuinely exciting wave of pharmacological research targeting the mechanism of PTSD itself — not just managing symptoms, but intervening in how traumatic memories work at the molecular level.

Scientists at the Institute for Basic Science in South Korea recently identified a new driver of PTSD: excessive GABA produced by astrocytes — the star-shaped support cells in the brain — that impairs the brain’s ability to extinguish fear memories. This is a meaningful shift from the standard neuron-centric view of psychiatric disease. Astrocytes have largely been treated as passive support staff. Turns out they may be actively making things worse.

The team found that a drug called KDS2010, which blocks the enzyme responsible for this abnormal GABA production, reversed PTSD-like symptoms in mice. KDS2010 is currently in Phase 2 clinical trials in humans, and has already demonstrated a favorable safety profile.

Separately, the field of psychedelic-assisted psychotherapy continues to produce compelling data for both PTSD and depression. Ketamine, MDMA, and psilocybin have all demonstrated significant reductions in PTSD symptoms over short treatment periods, attributed to their rapid onset and their ability to promote neural plasticity — essentially making traumatic memories more malleable and easier to process. Psilocybin is under active investigation for depression. Ketamine, in its nasal spray form Spravato, has been FDA-approved since 2019.

There’s also ALTO-100, a drug developed using machine learning to identify the patients most likely to benefit. It targets brain-derived neurotrophic factor (BDNF), a protein critical to synaptic plasticity, and is designed to restore the neural flexibility that depression disrupts. It’s now in a Phase 2b trial for major depressive disorder.

A quick summary of the pharmacological frontier:

• KDS2010: targets astrocytic GABA; Phase 2 trials underway

• Psilocybin: being investigated for treatment-resistant depression and PTSD

• ALTO-100: AI-assisted patient selection; targets BDNF pathways

• Caplyta (lumateperone): already used for schizophrenia and bipolar disorder, showing strong Phase III results for MDD

AI, access, and who actually gets these treatments 🌍

All of this progress runs into a practical wall: access. The most effective treatments — TMS, DBS, psychedelic-assisted therapy — remain concentrated in research hospitals, major cities, and places with good insurance. Veterans, low-income patients, and rural communities often get SSRIs and a waiting list.

Stanford recognized this problem explicitly. The newly launched CREATE Center, funded by an $11.5 million NIH grant, is building large language model tools specifically to extend the reach of evidence-based PTSD therapy. PTSD affects nearly 7% of the U.S. population, and many people — especially in rural areas and under-resourced communities — have no access to the psychotherapies that work best. The CREATE Center’s tools are designed to coach therapists, support patients between sessions, and help clinics implement new treatment protocols without requiring extensive retraining.

Johannes Eichstaedt, a faculty fellow at Stanford’s Institute for Human-Centered AI, put it plainly: “Large language models are not ready to act as stand-alone therapists, but there’s a lot of potential to provide support to humans to improve care for patients.” That distinction matters. AI as therapist is both overblown and probably counterproductive. AI as infrastructure — scheduling, coaching, training, triage — is a very different and much more achievable proposition.

If you’re thinking about the broader picture of consumer-facing neurotech — not just clinical tools but devices you can actually use — 5 Neurotech Devices You Can Actually Buy Today is a useful companion piece.

The things to watch in the access debate:

• At-home tDCS and neurofeedback devices are already shipping to consumers, and some clinics are experimenting with prescribing them

• In 2025, disclosed funding in neurotechnology surpassed $1.3 billion, which should accelerate both device development and coverage negotiations

• Insurance coverage for home neurotech devices is still being fought out, but the conversation is actively happening

• Telehealth PTSD programs using VR exposure without brain stimulation are already reaching patients who’d otherwise go untreated

The technology is outpacing the distribution system — which isn’t new, but it’s especially frustrating when we’re talking about conditions as acute as PTSD and depression. Suffering doesn’t pause while insurance companies update their coverage policies.

Here’s the question I keep coming back to: we now have treatments with 80%+ response rates for a condition that’s been treatment-resistant for generations. The bottleneck isn’t science anymore. So what is the bottleneck — and who’s responsible for fixing it?

Elite athletes have always trained the body to its limits. Ice baths, heart rate monitors, VO2 max testing, sleep tracking — everything measurable gets measured. But ask a neuroscientist what separates a good shooter from a great one, and they’ll point to the brain, not the biceps. The peak state athletes chase — that feeling of frictionless focus, zero inner chatter, pure execution — has a measurable neural signature. And now, for the first time in history, you don’t need a research lab or a sports psychologist to access it. 🧠

The devices are real. The science behind them is young but accelerating. A 2025 meta-analysis published in the Scandinavian Journal of Medicine & Science in Sports reviewed 25 studies on EEG neurofeedback training and motor performance — and found consistent, meaningful gains in precision sports like golf, shooting, and athletics. Another 2024 systematic review in Brain Sciences confirmed improvements in reaction times, cognitive performance, and emotional regulation across swimming, judo, rifle shooting, and more. The effect isn’t magic. It’s operant conditioning — applied to your neurons.

So what exactly can you buy right now, strap to your head, and use to rewire your attention, sharpen your focus, or finally get your sleep architecture dialed in? Here’s an honest breakdown.

What neurofeedback actually does (and why athletes care)

Before you spend $499 on headphones that read your brainwaves, it helps to understand what’s going on underneath the electrodes. 🔬

Neurofeedback is a form of biofeedback where your brain activity — measured in real time via electroencephalography (EEG) — gets fed back to you as a signal. A sound. A visual. A game that reacts to your focus level. The idea is simple: when your brain produces a desired pattern, it gets rewarded. Over time, it learns to produce that pattern on command. This is operant conditioning, the same principle Pavlov used, just pointed inward.

The brainwave frequencies athletes care most about:

• SMR (Sensorimotor Rhythm, 12–15 Hz): Associated with motor stillness and focused readiness. Elite shooters and golfers tend to show higher SMR right before execution. Training this frequency may reduce what researchers call neural “noise.”

• Frontal midline theta (4–8 Hz): Linked to attention, flow states, and flexible cognitive control. A 30-minute theta neurofeedback session was enough to improve motor performance and flow experience in a 2022 study in the Journal of Cognitive Enhancement. That’s a remarkably short runway.

• Alpha (8–13 Hz): The relaxed-but-alert state. The mental posture of a calm, confident performer.

• Beta (15–30 Hz): Active thinking, focus, engagement — also the zone where overthinking lives.

The psychomotor efficiency hypothesis — the theoretical backbone of most sports neurofeedback research — suggests that expert performers activate exactly the brain regions they need, and suppress the ones they don’t. Less cognitive noise equals better execution. It’s not about thinking harder. It’s about thinking cleaner. 💡

That said, neurofeedback results aren’t guaranteed. The research is honest about this: some protocols work better for some athletes in some sports. Individual baseline brainwave patterns matter. Protocol design matters. And there’s still not enough large-scale, randomized controlled trial data to call any particular consumer device a proven performance tool. Keep that in mind as you read what follows.

The Muse S Athena: the meditation headband that got serious

For years, the Muse headband from Canadian company InteraXon was the approachable consumer EEG device — comfortable, app-connected, popular with meditators and curious self-quantifiers. Over 500,000 users globally, according to the company, including clients from NASA, Harvard, and Mayo Clinic. Then in March 2025, they launched something more interesting. 🧘

The Muse S Athena is the first consumer wearable to combine EEG with functional near-infrared spectroscopy (fNIRS). That second sensor type measures blood oxygenation in the brain — essentially tracking how hard your brain is working, not just what state it’s in. Nathaly Arraiz Matute, Hardware Engineering Manager at Muse, described the dual-signal approach as unlocking a deeper picture of how the brain is functioning, focusing, and recovering.

What the Athena actually tracks and trains:

• Cognitive strength training — sessions designed to build mental endurance through real-time neurofeedback

• Sleep tracking with overnight EEG, detecting sleep stages, spindles, and K-complexes

• Focus sessions with fNIRS feedback showing cognitive effort in real time

• Heart meditation and breath meditation using PPG and accelerometer data

• Smart Wakeup — waking you at the lightest point in your sleep cycle

The base Muse 2 (around $249) still uses seven EEG channels and remains one of the most researched consumer EEG platforms on the market — used in published clinical trials. Researchers at ResearchGate consistently recommend it for sleep studies, attention classification, and general neuroscience work because of its solid signal quality from dry electrodes and its compatibility with both LSL and OSC real-time streaming. The Athena sits at roughly $449 and adds the fNIRS layer on top. 🔬

Is it going to make you a better golfer? Not automatically. But it can show you what calm, focused, recovered mental states actually look like — and train you to reach them faster and hold them longer. For anyone who’s ever blown a competition not because their body failed, but because their head was loud, that matters.

Neurable MW75 Neuro LT: the headphones that watch while you work

The idea sounds absurd until you see it working: headphones that track your brain activity while you listen to music, sit in meetings, study, or train. That’s the pitch of Neurable and its MW75 Neuro LT — and honestly, it’s not as absurd as it first sounds. 🎧

Neurable has spent a decade refining AI algorithms that extract meaningful EEG data from sensors embedded in headphone earcups. Where traditional EEG labs use twenty-plus sensors across the scalp, Neurable gets comparable results from 12 soft-fabric EEG channels built into the ear pads. The original MW75 Neuro — developed in partnership with audio brand Master & Dynamic — launched at $699. The LT version, released in late 2025, is 12% lighter and priced at $499, bringing it level with Apple AirPods Max but with a use case Apple can’t touch.

What the MW75 LT actually delivers:

• Cognitive Snapshot — a two-minute reading that tells you whether now is a good time for deep work or lighter tasks

• Focus tracking throughout the day, showing time spent in low, medium, and high focus states

• Brain Break prompts — the headphones detect mental fatigue before you feel it and suggest when to rest

• Anxiety Resilience and Cognitive Strain scores updated daily

• 22 hours of battery life (13 hours with EEG tracking active)

The Brain Break feature was tested in partnership with the Mayo Clinic. According to Neurable CEO Dr. Ramses Alcaide, subjects who acted on the app’s rest suggestions were 20% more productive and reported feeling 50% happier by end of day compared to those who didn’t. That’s a meaningful number if it replicates at scale, though the sample sizes in these early studies are still small.

SoundGuys, which tested the headphones over two weeks, found the focus data genuinely surprising — the objective picture of their attention diverged sharply from how focused they felt. That gap between subjective experience and neural reality is exactly what makes these devices interesting. If you can see when you’re actually in flow versus when you only think you are, you can start optimizing for the real thing. 💡

What are you using to track your cognitive performance right now — a subjective journal? A feeling? There might be a better way.

Myndlift and the Muse ecosystem: clinical-grade neurofeedback at home

If the consumer Muse experience feels a bit shallow — and sometimes it does, especially for people with specific cognitive goals — there’s a meaningful upgrade hiding inside the same hardware. Myndlift is a neurofeedback platform that plugs directly into the Muse headband and converts it into a clinical-grade training tool. ⚡

The upgrade includes:

• qEEG brain mapping — a full-spectrum look at your baseline brainwave profile

• Customized training protocols built around your specific goals (attention, sleep, anxiety, performance)

• Session types including games, movies, and music that adapt in real time based on your brain activity

• An additional electrode sent with the subscription kit, filling a signal gap and meaningfully improving scan quality

• Clinic-grade progress tracking suitable for both individual users and professional Neuro Coaches working with clients

This matters for athletes because generic neurofeedback — train your alpha, relax more — may not match your specific deficits or your specific sport. Myndlift unlocks the ability to target the exact frequency bands the research actually connects to performance. A golfer and a swimmer likely need different protocols. And precision, as the Frontiers in Psychology research makes clear, is fundamental to whether neurofeedback produces real performance gains or just expensive placebo.

The combination of a $249 Muse 2 plus a Myndlift subscription is probably the most research-aligned consumer neurofeedback setup available today. It’s not cheap. But compared to what serious athletes spend on physical performance tools, it’s modest. 🧬

The honest limits of what these devices can do

This is where a lot of consumer neurotech coverage goes wrong — it skips straight to “train your brain like a Navy SEAL” and forgets the part where science asks hard questions. Let me be direct about what we actually know. 🔬

The evidence base for consumer EEG neurofeedback is promising but inconsistent. Not every protocol works for every person. As the 2024 Brain Sciences systematic review found, some athletes showed no improvement in attention or reaction time despite completing full neurofeedback programs. The researchers pointed to protocol variability, individual differences in baseline brain activity, and sample sizes too small to draw universal conclusions.

Specific things worth keeping in mind:

• Consumer EEG devices have fewer channels and lower spatial resolution than clinical systems. The Muse 2 has four EEG channels. A research-grade cap might have 64 or 128. More channels means more precise signal localization.

• Dry electrodes (no gel) are more comfortable but produce noisier signals. Good enough for many applications. Not clinical-grade for all of them.

• Results require commitment. The research consistently shows that neurofeedback gains come from sustained practice across multiple sessions — not one or two sessions. The typical protocol in sports studies runs ten to forty sessions.

• Opportunity cost is real. As neuroscientist Anna Wexler noted in her IEEE Pulse commentary, using one therapy to the exclusion of other effective options carries its own risk, even when the chosen therapy isn’t harmful.

None of that means you shouldn’t try these devices. It means you should try them with calibrated expectations. They’re tools for awareness and training, not instant upgrades. The brain responds to practice, not purchase. 💊

And yet — the data from the neurofeedback market research published by Reanin shows the sector at $299.95 million in 2025, projected to reach $663.10 million by 2032. Around 65% of providers now use platforms with adaptive feedback and wearable EEG hardware. The professional world is buying in. That’s worth paying attention to.

For more on where this technology is headed, the 5 Neurotech Devices You Can Actually Buy Today breakdown over at NeurotechMag covers some additional options — including in-ear EEG systems that may change the game for daytime use. And if you want a wider view of why this moment matters, 6 Signals That Neurotech Is Reaching a Tipping Point puts the consumer device wave in context.

The body has had performance tracking for decades. The brain is finally catching up. The question isn’t really whether these tools will matter — it’s whether you’ll start before your competitors do.

Picture someone who thinks “neurotech” means Elon Musk’s surgeons drilling holes in people’s skulls. Technically not wrong. But it’s like saying “computers” just means supercomputers in government bunkers. The reality is messier, quieter, and far more interesting. Neurotechnology — any device that reads, writes to, or otherwise messes with your nervous system — has been creeping into ordinary life for years. Researchers describe a “Neurotechnology Shift”: a transformation in which brain-machine technology migrates from labs and hospitals into nonclinical settings, making the brain itself an everyday interface. The prosthesis, as one researcher puts it, is becoming infrastructure.

You probably own something that qualifies right now. Here are five ways neurotech is already in your life — and why that’s both more exciting and more complicated than the headlines suggest.

1. The cochlear implant: the original brain hack hiding in plain sight 🧬

The cochlear implant is so old and so common that people have forgotten it’s genuinely radical technology. It skips a broken sense organ entirely and talks directly to the auditory nerve — which is about as close to sci-fi as medicine gets. Cochlear implants stimulate the auditory nerve to allow profoundly deaf people to perceive sound, and they’re now approved for infants as young as six months, dramatically improving language development. Let that sink in. A six-month-old with a computer wired into their nervous system. Somehow we treat this as unremarkable.

The same is true of deep brain stimulation, the other veteran of medical neurotech. DBS has been transforming the lives of people with Parkinson’s disease and other neurological disorders for more than 30 years — it’s essentially a cardiac pacemaker, but for the brain. Surgeons implant a device near the collarbone that sends electrical pulses to specific brain regions, smoothing out the tremors and rigidity that define Parkinson’s. It’s not a cure. But for many patients, it’s the difference between walking and not walking.

What’s new is that these systems are getting smarter. Adaptive deep brain stimulation uses a person’s individual brain signals to control the electric pulses it delivers — more personalized and precise than older methods. Medtronic’s BrainSense Adaptive DBS, which earned FDA approval in early 2025, takes this further: with more than 40,000 DBS patients served worldwide on Percept devices, the launch of adaptive DBS represents the largest commercial deployment of brain-computer interface technology ever. Not a pilot study. Not a clinical trial. A product, shipping now.

Key things these implants already do:

• Restore hearing in babies and adults who would otherwise experience profound deafness

• Reduce tremors and stiffness in Parkinson’s patients, sometimes dramatically

• Treat epilepsy through vagus nerve stimulation, which sends electrical pulses up through the neck

• Manage chronic pain via spinal cord stimulation

• Adjust stimulation in real time, responding to the brain’s own signals

Think about that list for a second. None of these belong to the future. They’re already in millions of people’s bodies.

2. That meditation headband on your nightstand 🔬

If you’ve looked at the wellness section of any tech site recently, you’ve probably stumbled across EEG headbands: soft, comfortable devices that sit on your forehead and measure your brainwaves in real time. They’re not toys. They’re legitimately sophisticated pieces of neurotechnology, now priced for ordinary consumers.

InteraXon’s Muse S Athena, the latest model from the company that essentially invented the consumer EEG category, combines EEG sensors with fNIRS (functional near-infrared spectroscopy) — a technology that measures blood oxygenation in the brain. An earlier version of the Muse S performed comparably to standard laboratory sleep-testing equipment, which is a remarkable thing to say about a $500 headband you buy on Amazon. Interaxon’s co-founder Chris Aimone says many of the company’s research partners are interested in sleep science, noting the S Athena can function as an at-home sleep monitor for assessing disorders like sleep apnea.

Then there’s Elemind, which takes a more aggressive approach. Rather than just measuring your brainwaves, it actively pushes them in a different direction. Elemind measures EEG brain signals and delivers precise acoustic feedback, custom-tailored to your brain’s own natural rhythms — working like a noise-cancellation system for the brain, interrupting the brainwaves that keep you awake and boosting the waves that promote deep sleep. The company claims it helped 76% of study participants fall asleep faster. That’s either impressive neuroscience or impressive marketing — probably some of both.

What’s worth noting:

• Consumer EEG devices are not medical devices and don’t face the same regulatory scrutiny

• Neurofeedback research shows modest benefits for attention and anxiety; meta-analyses vary, and the effect sizes aren’t always huge

• The FRENZ Brainband from Earable Neuroscience won a third consecutive CES Innovation Award in 2025 and claims 70% improvement in focus over 30 days in company trials — which sounds great, and should also prompt questions about who ran those trials

• The Muse S Athena costs around $500; premium systems like Sens.ai run closer to $1,500

I’m genuinely excited by where this category is heading. But I also think people deserve to know that “clinically inspired” and “clinically proven” are different things. Ask for the peer-reviewed data. It sometimes exists. Sometimes it doesn’t. 🧪

Do you already own one of these headbands? What’s your honest take on whether it actually works?

3. Your wrist already reads your nerves ⚡

This one might be the most surprising item on the list, because the product in question isn’t marketed as neurotech at all. It’s sold as a pair of glasses.

In late 2025, Meta launched Ray-Ban Display — AI smart glasses with a full-color display in the lens. But the really interesting part isn’t the glasses. Each pair comes with the Meta Neural Band, an EMG wristband that translates the signals created by your muscles — even subtle finger movements — into commands for your glasses. EMG stands for electromyography, and it measures the electrical activity your muscles produce when they move. It’s a technology that’s been used in clinical settings for decades. Meta brought it to Best Buy.

Here’s how it works: EMG sensors in the Meta Neural Band detect signals based on what users intend to do — clicking, scrolling, swiping — and machine learning turns those signals into digital commands, with response times measured in milliseconds. The neural networks were trained on data from nearly 200,000 research participants. And in a detail that I find both impressive and slightly unsettling: the system works even before a movement is visually perceptible, allowing it to respond to your intentions rather than waiting for completed gestures.

At CES 2026, Meta showed where this is going next. The company teamed up with Garmin to demonstrate using the Neural Band to control a car’s infotainment system, and announced research partnerships to test control of smart speakers, blinds, thermostats, and locks through wrist gestures. The accessibility angle is real too: the Neural Band is sensitive enough to detect subtle muscle activity even for people who can’t fully move their hands, which opens serious potential for people with ALS, muscular dystrophy, and similar conditions.

What to watch here:

• The $799 Ray-Ban Display bundle is available now in the US

• EMG processing happens entirely on-device — your gesture data doesn’t leave the wristband

• Meta has been researching this for years; this isn’t rushed consumer tech

• The same fundamental technology could eventually let you control almost any smart device with a twitch of your finger

4. The algorithm that already knows your mental state 📈

You might not own a headband or a wristband. But if you’ve ever used a mental health app that claims to track your mood or cognitive state over time, you’ve touched the edge of the same territory. And if you work in a setting that uses attention-tracking tools, you may be closer to the center than you’d like.

Some schools are using neurotechnology for the purpose of tracking students’ attention, while others are exploring how it can support education. The ethics of that vary enormously depending on how transparently it’s done and whether students have any choice in the matter. In workplace settings, some companies are beginning to explore neurotechnology to track productivity — a development that should make anyone with a functioning sense of self-preservation slightly uncomfortable.

On the more benign side, Neurable — which raised a $35 million Series A at the end of 2025 — makes EEG-equipped headphones that track cognitive health as you wear them. The company’s MW75 Neuro LT provides real-time insights on mental fatigue, cognitive recovery, and focus state detection. The vision: brain data as accessible as heart rate or sleep tracking, woven into the devices you already use every day.

This is where neurotech gets philosophically tricky:

• Your heart rate is physical. Your focus levels and cognitive state are a lot closer to thoughts.

• Companies that gather neural data early have access to a dataset unlike anything in tech history — neural data is unique, sensitive, and high-dimensional; companies that label it early can train AI models that decode brain patterns and create predictive insights no one else can touch.

• The Centre for Future Generations notes that consumer neurotech devices don’t face the same safety and efficacy regulations as medical devices — meaning the data they collect and the claims they make aren’t always held to the same standard

• Consumer neurotech firms now account for 60% of the global neurotechnology sector, according to research from the Centre for Future Generations — and they’ve outnumbered medical firms since 2018

If you’re using apps or wearables that claim to understand your cognitive state, it’s worth asking: who owns that data, how long they keep it, and what they’re building with it. These aren’t hypothetical questions anymore. 🌐

5. Gaming controllers that respond to your brain, not just your thumbs 🚀

The gaming industry has always been an early adopter of weird human-machine interfaces. Motion controls, haptic feedback, eye tracking — they all started in games. Neurotech is no different.

EMOTIV, one of the oldest names in consumer BCI, has sold EEG headsets for gaming since 2008. At CES 2025, EMOTIV CEO Tan Le launched wireless EEG earbuds designed for continuous brain monitoring — smaller, more practical, and no longer requiring you to look like you’re in a sleep lab. The company’s pitch: “We need to put technologies like this into the hands of everyday people so that we can start to track and improve our cognitive well-being.”

Meanwhile, Naqi Logix’s Neural Earbuds — an Innovation Honoree at CES 2025 — offer hands-free device control through neural signals, without implants or voice commands. Originally designed for people with limited mobility, the technology also aims to help general users with multitasking. You control your phone by thinking about controlling your phone. Sort of. The accuracy and latency constraints on non-invasive systems are real, and anyone who tells you otherwise is selling you something.

What’s actually shipping for gamers right now:

• Neurable’s MW75 Neuro headphones track cognitive load and flag when you’re burning out — useful for competitive players who grind for hours

• The FRENZ FocusFlow app uses real-time brainwave tracking to deliver personalized audio therapy for focus, with CES 2025 recognition in digital health

• NextMind, acquired by Snap Inc., explored visual cortex BCIs for gaming control before Snap folded it into broader AR research

• OpenBCI makes open-source EEG hardware popular with developers and researchers who want to build their own brain-controlled applications

The BCI market — just the brain-computer interface slice, not all of neurotech — is projected to hit $2.11 billion by 2030, according to Mordor Intelligence, growing at over 10% annually. The gaming and esports applications will probably be a significant part of that. Because when better concentration literally translates to wins and losses, the incentive to figure out how your brain works at its peak is extremely real.

What would you do if your game could tell you when you were in the zone — and when you needed a break before making a costly mistake?

The honest answer is that this technology is already sophisticated enough to tell you exactly that. Whether you trust it with your most personal data is, for now, entirely up to you. That probably won’t be true forever — and that’s exactly why paying attention to neurotech right now matters more than most people realize. 🧠

As you read this, someone is probably wearing a device that reads their nervous system. Maybe it’s a cochlear implant. Maybe it’s a Muse headband. Maybe it’s the wristband Meta is quietly turning into a new computing paradigm. The technology isn’t waiting for society to catch up. The question worth sitting with isn’t “will neurotech be in my life?” It’s “what do I actually want it to do there?”

Imagine planning your day around the possibility that, at any moment, without a flicker of a warning, your brain might short-circuit. No countdown. No aura. Just the floor rushing up to meet your face. For the roughly 50 million people worldwide living with epilepsy, that’s not a thought experiment — it’s Tuesday. About 30 to 40 percent of them have drug-resistant epilepsy, meaning medication has already failed them and seizures keep coming regardless. The only thing missing, the thing patients and neurologists have wanted for decades, is a forecast. A weather warning for the brain. 🧠

That forecast is no longer purely hypothetical. A convergence of machine learning, implantable neurotechnology, and increasingly clever wearable sensors is making it possible to predict seizures before they happen — sometimes minutes in advance, sometimes hours. It’s not perfect. It doesn’t work for everyone. But the science has moved fast enough that real devices are shipping, real studies are reporting real numbers, and real patients are changing how they live their lives because of it.

Detection vs. forecasting: why the distinction actually matters

People tend to use “seizure detection” and “seizure prediction” as if they mean the same thing. They don’t, and the difference is enormous. 🔬

Seizure detection means a device notices a seizure is already happening and alerts a caregiver. That’s useful — it can speed up emergency response and reduce the time someone lies unconscious on a bathroom floor. But it doesn’t give the patient any agency. The event has already started.

Seizure forecasting is a different animal entirely. It means a device reads physiological signals — brain waves, heart rate, skin conductance, temperature — and tells you before anything goes wrong that your risk is elevated. A few minutes of warning, according to researchers at Mayo Clinic, can mean:

• Calling a caregiver or family member

• Sitting or lying down in a safe place

• Avoiding a car, a swimming pool, or a busy street

• Potentially triggering an automatic intervention like brain stimulation

That’s not a trivial difference. That’s the difference between being a passive victim and having some control over your own safety. Dr. Benjamin Brinkmann, a biomedical engineer at Mayo Clinic, has put it bluntly: the idea is simple — give people a warning. His team, working with both smartwatches and implanted devices, has correctly predicted approximately 75% of seizures with few false alarms in early studies. 🎯

The reason this is hard, though, is worth understanding. A seizure isn’t a discrete event that switches on suddenly. It’s the culmination of shifting electrical states in the brain, and those states can be nudged by sleep quality, stress, hormones, medication timing, and factors nobody has identified yet. Teaching a machine to read those signals reliably — across different patients, different seizure types, different lives — is genuinely difficult.

The wearables getting closest to the market

The most accessible tier of this technology lives on your wrist or behind your ear, and a few companies have gotten close enough to shipping that patients can actually buy something today. 💡

Empatica’s EpiMonitor, the successor to the widely recognized Embrace2, is the only FDA-cleared wearable for seizure detection currently available for purchase in the US. The system pairs the EmbracePlus medical smartwatch with a companion app, detects generalized tonic-clonic seizures via a smart algorithm with a 98% accuracy rate, and has up to seven days of battery life. It monitors electrodermal activity, temperature, accelerometry, and movement. Right now, it’s primarily a detection device. But Empatica is actively running a first-of-its-kind study to develop a full seizure forecasting algorithm using real-world data from EpiMonitor users across the US — which suggests the detection hardware is already collecting the data that forecasting models need.

Then there’s EPISERAS, a device from Spanish startup mjn-neuro that announced a European launch partnership with Neuraxpharm in late 2025. It’s an in-ear sensor, discreet as a hearing aid, that continuously records brain activity and fires an alert minutes before a seizure occurs. The company has been building this since 2014, has clinical evidence from multicenter studies across Spain, the UK, and Germany, and calls it the first digital health solution designed for real-time early detection in both ambulatory and home-care settings. The European launch is scheduled for 2026.

And then there’s Theta Neurotech, a startup out of the University of Chicago with a device that looks almost mundane: two adhesive sensors worn behind the ears. Under the hood, a machine-learning model detects subtle neurological shifts and can alert patients up to two hours before a seizure. Two hours. That would change daily life in fundamental ways.

Key differences between these wearable approaches:

• EpiMonitor (Empatica): FDA-cleared, commercially available now, currently detection-focused, forecasting study underway

• EPISERAS (mjn-neuro/Neuraxpharm): in-ear EEG, real-time risk prediction, European launch 2026

• Theta Neurotech Patch: behind-the-ear EEG sensors, up to 2-hour advance warning, still in development

• Brain Sentinel SPEAC: arm-worn sEMG monitor, the other FDA-cleared non-EEG option, detection-focused 🧬

Have you tried any epilepsy wearable, or know someone who has? The gap between clinical trial results and real-world usability is often the most telling data point of all — drop your experience in the comments.

The implant that talks back to your brain

Wearables are compelling for accessibility, but they face a stubborn limitation: they’re reading peripheral signals — skin conductance, movement, heart rate — and inferring what’s happening in the brain. Implants skip the inference step entirely. ⚡

NeuroPace’s RNS System is the most mature player in this space. It’s a closed-loop brain-computer interface: a neurostimulator implanted in the skull, with leads placed directly at the seizure focus. The device continuously monitors brain waves, recognizes each patient’s unique seizure-onset pattern, and responds with brief electrical pulses to interrupt the abnormal activity before a full seizure can develop. It’s personalized from day one, since every patient’s brain has its own electrical fingerprint.

The long-term data on the RNS System is genuinely striking. At the 2025 American Academy of Neurology meeting, NeuroPace presented three-year post-approval study data from 324 patients across 32 centers — the largest FDA-reviewed prospective neuromodulation trial ever conducted. The results showed:

• 82% median seizure reduction at three years

• 42% of patients seizure-free for six months or longer

• 62% median seizure reduction achieved as early as six months post-implant

• Continued improvement over time, not a plateau

That last point matters. Most seizure medications provide their best response early and then level off. The RNS system keeps getting better as it learns its patient’s brain patterns over months and years. There’s something almost elegant about a device that improves with experience.

The tradeoff, of course, is surgery. The implant isn’t a good fit for everyone, and it requires patients to upload their brain data regularly via a remote monitor. It’s also currently FDA-approved only for adults 18 and older with focal-onset seizures, though NeuroPace has active research into Lennox-Gastaut Syndrome, a severe childhood epilepsy that has historically had very few treatment options. The company received a $9.3 million NIH BRAIN Initiative grant to fund that feasibility study.

Why your brain runs on a schedule (even if you don’t know it)

Here’s something that might reshape how you think about seizures: they aren’t random. Or rather, they’re less random than most patients believe. 📈

Research published in Clinical Epileptology and across multiple journals has shown that seizure patterns in many patients follow circadian rhythms — daily cycles tied to the sleep-wake cycle — and multidien rhythms, meaning multi-day patterns that can span weeks or even months. A 2024 review in Frontiers in Neurology notes these patterns are present in as many as 30% of people with drug-resistant epilepsy. Some patients have weekly seizure cycles; others monthly. Some have cycles that correlate with menstrual hormones. Some have cycles that nobody has explained yet.

This rhythmicity is why seizure forecasting is even theoretically possible with non-invasive wearable devices. If your brain runs a loosely predictable schedule, then a machine learning model fed weeks of your heart rate variability, skin conductance, temperature, and movement data can start to spot where you are in that cycle — even without reading your EEG directly. A 2021 study published in Scientific Reports from Mayo Clinic showed a wrist-worn LSTM neural network achieved an AUC-ROC of 0.80 for seizure forecasting, beating random prediction in 5 of 6 patients studied in real ambulatory settings, with concurrent confirmation from an implanted recording device.

The AI isn’t predicting a specific moment. It’s estimating risk windows — periods where probability is elevated enough to warrant caution. Think of it less like a car’s collision warning and more like a weather app saying 70% chance of rain. You don’t know exactly when it’ll rain. You bring an umbrella anyway.

Key signals wearable forecasting systems are currently learning to read:

• Heart rate variability and cardiac rhythms synced with seizure cycles

• Electrodermal activity (skin conductance), which reflects autonomic nervous system shifts

• Body temperature and sleep quality patterns

• Accelerometry for movement and rest cycles

• Multiday rhythms identified from weeks of continuous data collection 🔬

The hard part is that these rhythms are deeply individual. A model trained on a population doesn’t translate cleanly to any single patient. The best systems are therefore personalized, trained on weeks of data from the specific patient before they start generating forecasts. That’s a slow, data-hungry process — but that’s exactly what devices like EpiMonitor and the NeuroPace RNS are designed to enable.

What’s still missing, and why this isn’t solved yet

Let’s be clear about something: this technology is real, and it is genuinely improving lives. But the honest picture is messier than the press releases suggest. 🧬

The clearest gap is coverage. Current forecasting and detection systems work best — sometimes only — for generalized tonic-clonic seizures, the convulsive type that’s visually dramatic and physiologically distinct. Focal aware seizures, absence seizures, and other subtler types are far harder to detect, let alone predict, because their physiological footprint in peripheral signals is much smaller. A 2025 scoping review from Weill Cornell Medicine in Qatar, published in JMIR, found that while AI-driven wearables show significant promise, the field still struggles with standardized validation methods, small study populations, and the challenge of deploying energy-efficient algorithms in real-world settings.

There’s also a false alarm problem. Every false alarm erodes trust. If a device alerts you five times and none of them result in a seizure, you start ignoring alerts on the sixth — the one that’s real. Getting sensitivity and specificity right at the same time, across diverse patients, outside of controlled hospital conditions, remains a stubborn engineering challenge.

And then there’s the question of what to do with a warning. If you get a 20-minute heads-up, what happens next? Sitting down is a good answer. But the bigger, more interesting answer is closed-loop intervention — where the warning itself triggers a treatment response, like a burst of medication delivered precisely, or targeted brain stimulation via an implanted device. That’s the direction Dr. Brinkmann’s work at Mayo Clinic is explicitly pointed. The idea of a seizure warning system that also prevents the seizure, automatically, without the patient having to do anything, is as compelling as it sounds.

Consider this: if a wearable could give you a reliable 30-minute window of elevated risk and also automatically notify emergency services or a caregiver, would you wear it every day? And what would it cost — financially, emotionally, in terms of the constant surveillance of your own body — to live with that kind of system forever? That question might be harder than the engineering. If you’re living with epilepsy, or close to someone who is, what would a reliable seizure forecast actually change for you? The comments are open.

For anyone wanting to understand how devices like these fit into the broader trajectory of brain-computer interfaces, NeurotechMag’s own look at five neurotech devices you can actually buy today and the signals that neurotech is reaching a tipping point are worth your time. The seizure prediction space isn’t a niche medical story — it’s one of the clearest proofs that neurotechnology has moved from lab curiosity to something that hands people real agency over their own biology.

The next step for the field isn’t more research showing the technology can work. It’s proving it works reliably enough, cheaply enough, and comfortably enough that the 90% of epilepsy patients who currently have no warning at all can finally have one. That number — 90% with no warning — is the number the whole field is trying to shrink.

The first time Noland Arbaugh played online chess using only his thoughts, it probably felt like the closing scene of a science fiction film. Arbaugh, paralyzed from the shoulders down after a diving accident, received a Neuralink brain implant in January 2024. Within weeks, he was moving a cursor, browsing the web, and winning games of Civilization VI, all without lifting a finger — because he couldn’t. By September 2025, twelve people worldwide had received Neuralink implants, all with severe paralysis, all now controlling digital tools through thought alone.

The race to merge humans with machines is no longer theoretical. It’s clinical. It’s funded. And it’s getting competitive in ways that would make even Musk nervous — if he were capable of that.

This is a fight with several distinct fronts: surgical risk tolerance, electrode counts, regulatory strategy, and something much thornier — the question of whose brain data ends up in whose database. The companies involved are all betting on different versions of the future, and it’s genuinely unclear which version wins. Let me walk you through the contenders. 🧠

Neuralink: the loud, fast, and expensive bet

Neuralink’s The Link implant is about the size of a quarter, 23mm wide and 8mm thick. It sits where a small piece of skull used to be, connected to the brain by hair-thin electrodes threaded into the tissue. The device reads electrical signals from neurons and translates them into digital commands in real time. Think of it as a Bluetooth adapter for your motor cortex.

The ambition here is enormous. Musk has called it a potential “Fitbit in your skull,” which is maybe the most reductive description of brain surgery ever offered by a tech billionaire. The longer-term goal — human-AI symbiosis, merging biological and artificial intelligence — is harder to square with the current clinical reality of helping ALS patients type messages to their families. STAT News reported in January 2026 that Neuralink’s public rhetoric about human augmentation actively worries the company’s medical device competitors, who fear it muddies FDA relationships for the whole industry. That’s a real problem, not a hypothetical one. 🔬

Still, the momentum is hard to ignore:

• 12 humans implanted as of September 2025, ranging from ALS patients to quadriplegics with spinal cord injuries

• ALS patient Brad Smith now uses The Link as his primary communication tool, typing entirely with his brain

• The company raised $650 million in Series E funding in 2025, pushing its valuation to $9 billion

• International trials now run in the UK (at University College London Hospitals and Newcastle), Canada, and the UAE at Cleveland Clinic Abu Dhabi

• Neuralink received an FDA Breakthrough Device Designation for its speech restoration technology in 2025

On December 31, 2025, Musk announced that Neuralink would begin high-volume production of brain implants in 2026, with a mostly automated surgical procedure. The new approach threads electrodes through the dura — the tough membrane covering the brain — without removing it, which is a genuine technical step forward. ⚡

Early thread retraction was a real issue in Arbaugh’s surgery, with some of the thin electrodes pulling back from brain tissue and reducing the effective electrode count. Neuralink quietly resolved much of this over time, but it’s a reminder that the gap between “functioning” and “reliable” in brain hardware is still wide.

What does this mean for you as a reader? If you’re a tech enthusiast tracking where serious money and serious medical need intersect, Neuralink is still the story. Whether it stays that way is another question entirely.

Synchron: the quiet contender winning on pragmatism

While Neuralink grabs headlines, Synchron is building a case for being the company that actually makes it to market first. Founded in 2012 by Thomas Oxley and Nicholas Opie, the Australian-American company has one decisive advantage over its competitor: it doesn’t require open brain surgery. 🩺

Synchron’s Stentrode is delivered through the jugular vein. It travels up through the blood vessels and settles beside the brain’s motor cortex, where it reads neural signals from the vascular wall. No craniotomy. No robot drilling through your skull. The tradeoff is bandwidth — the Stentrode picks up fewer signals than Neuralink’s deeply implanted electrodes — but for regulators and patients nervous about neurosurgery, that tradeoff looks awfully reasonable.

The company has already demonstrated impressive real-world results:

• Patients controlling an iPhone and Apple Vision Pro using thought alone

• One early US trial participant now commands Amazon Alexa without speaking

• Synchron demonstrated its BCI’s ability to control an iPad in August 2025, using Apple’s BCI Human Interface Device input protocol announced in May 2025

That last point matters more than it might seem. Apple built a software on-ramp for BCIs into its ecosystem. Synchron’s Stentrode is already compatible. Neuralink is not, at least not yet. When a company the size of Apple aligns itself with your hardware approach, that’s not just a partnership — it’s a distribution channel for every iPhone and Vision Pro on the planet.

Synchron is backed by Bill Gates, Jeff Bezos, and a $75 million investment round. Even Musk himself reached out to Synchron’s CEO Tom Oxley in 2022 during a period of Neuralink delays, exploring a potential deal. The conversation went nowhere. In retrospect, that looks like a missed shot.

Ask yourself: if you could gain the ability to control a digital device with your thoughts, but the choice was between a minimally invasive vascular procedure versus a robot drilling into your skull, which one would you pick? Because most people, when asked that question directly, choose the vein. And regulators seem to feel the same way.

Precision Neuroscience, Paradromics, and the crowded field

The BCI space isn’t a two-horse race, even if media coverage makes it look that way. Several other companies are moving fast and thinking differently about the hardware problem. 💡

Precision Neuroscience is the most interesting Neuralink-adjacent story here. Co-founded by Benjamin Rapoport, one of the eight original co-founders of Neuralink, the New York-based startup built the Layer 7 Cortical Interface, a thin-film electrode array that sits on the brain’s surface rather than penetrating it. The device looks like a piece of scotch tape. It’s flexible, reversible, and safer to remove than traditional deep-brain implants. Precision raised $102 million to advance AI-powered brain recording, and its total funding now sits at $147 million. Its initial target applications are stroke rehabilitation and treatment of refractory depression — both massive markets.

Then there’s Paradromics, an Austin-based company whose Connexus system can handle up to 1,600 channels of neural data, significantly more than current systems. Paradromics received FDA IDE approval for its Connect-One study in 2025, targeting speech restoration and computer control in people with severe paralysis. The Connexus implant was shown to record electrical brain signals and be removed intact in under 20 minutes during its first human procedure. That’s a meaningful safety feature when the device sits inside someone’s head.

A few others worth watching:

• BlackRock Neurotech has more total implanted users than Neuralink in absolute terms, and has operated for longer

• ONWARD Medical completed five successful BCI implants for spinal cord injury patients by late 2025, with procedures at a neurosurgery center in Lausanne, Switzerland

• Axoft (Cambridge, MA) performed its first-in-human BCI implant in April 2025

• Starfish Neuroscience is developing a wireless, battery-free chip designed to interact with multiple brain regions simultaneously, targeting Parkinson’s disease

That’s a lot of companies, a lot of approaches, and a lot of money. As NeurotechMag reported earlier this year, disclosed BCI funding exceeded $1.3 billion in 2025 alone, and the neurotechnology market is projected to grow from roughly $15–17 billion today to over $47 billion by 2035. This isn’t a niche. It’s an arms race with electrodes instead of missiles. 📈

The regulation question nobody wants to answer

Here’s what the breathless coverage of brain-computer interfaces tends to skip past: who owns the data your implanted device collects?

Neural data is not like your step count or your heart rate. Researchers have demonstrated that AI models can decode inner speech from brain signals with up to 74% accuracy. A 2024 study decoded neural activity while subjects listened to music, reconstructing the Pink Floyd song they were hearing through generative AI alone. Brain signals can already be used to infer what you’re thinking about, not just what you want to move. That is a fundamentally different category of information than anything data privacy law was designed to handle. 🔐

The US Senate noticed. In September 2025, Senators Chuck Schumer, Maria Cantwell, and Ed Markey introduced the Management of Individuals’ Neural Data Act — the MIND Act — which directs the FTC to study neural data governance, identify regulatory gaps, and recommend new protections. California, Colorado, Connecticut, and Montana have already amended their state privacy laws to include neural data. Chile went further, amending its constitution to protect brain activity as a fundamental right. In November 2025, UNESCO adopted a global Recommendation on the Ethics of Neurotechnology.

None of these frameworks are fast enough to keep pace with the hardware. The MIND Act is a study, not a law. UNESCO’s recommendation isn’t binding. The gap between what BCI devices can collect and what regulation currently restricts them from doing is enormous, and some legal scholars are openly skeptical that industry self-regulation will ever genuinely limit a technology sitting on a goldmine of intimate personal data.

Neuralink, specifically, draws scrutiny here. The company recently recruited a senior FDA official away from the regulatory office that oversees it — a move that competitors described to STAT News as “infuriating.” Whether that affects regulatory outcomes is unknown. That it created that level of reaction in a small, competitive industry is telling enough.

The ethics aren’t abstract. If you’ve ever wondered what it might feel like to have your thoughts treated as a data point, the infrastructure for that is currently being implanted into twelve people’s skulls. What’s your line? Where does “restoring lost function” end and “reading minds for profit” begin? That distinction is the hardest question in tech right now, and we’re not even close to answering it.

Who’s actually winning?

Here’s the honest answer: it depends entirely on how you define winning. 🏆

By media coverage and funding — Neuralink wins. Its $9 billion valuation, celebrity patients, and Elon Musk’s ability to generate headlines make it the reference point every other company in this space is measured against. Morgan Stanley’s private 2025 report argued Neuralink sits at the center of a technological shift society isn’t prepared for, spanning healthcare, defense, gaming, and investing.

By regulatory momentum — Synchron wins. Its endovascular approach carries fewer surgical risks, which is exactly what the FDA and international regulators want to see before they approve any device for broad use. Apple’s software partnership gives Synchron consumer distribution that no other BCI company currently has.

By technical ambition — the picture is murkier. Paradromics’ channel count, Precision’s reversibility, and Neuralink’s electrode density are all solving different versions of the same problem: how do you build a reliable, long-term, high-fidelity interface between biological neurons and digital systems? Nobody has solved it yet.

By patient impact right now — every company doing this work is winning, at least a little. Brad Smith, completely paralyzed and ventilator-dependent, types with his brain. Synchron’s patients play video games with their thoughts. People who lost their voice to ALS are starting to get it back. The competitive advantages that neurotech companies build are ultimately grounded in this — the ability to access and modulate the one system in the body no other technology touches.

The race isn’t over. In fact, it’s barely started. Neuralink plans to move to automated surgery and high-volume production in 2026. Its Blindsight implant — designed to restore vision for the completely blind by stimulating the visual cortex — is scheduled for its first patient trial this year. Synchron is launching a commercially available system. Precision wants to commercialize by 2025. The whole field is accelerating faster than the legal and ethical framework surrounding it.

Which brings me back to the only question that actually matters at the end of this: not “who is winning,” but “winning what, exactly?” If winning means the first company to put a chip in a healthy person’s brain so they can scroll Twitter faster, that’s a very different prize than building technology that gives a paralyzed parent back the ability to type a message to their kid. These companies claim to be after the second thing. History has a way of testing those claims.

What would make you consider a brain implant — and what would have to be guaranteed before you’d ever agree to it? Drop it in the comments. The answer matters more than most people think. 👇

For the broader context on where all of this sits in the neurotech market, this breakdown of tipping-point signals for neurotech is worth your time.

Imagine a job interview in 2035. Your competitor for the role has a neural implant that sharpens working memory, accelerates information retrieval, and reduces cognitive fatigue. You don’t. Not because you chose not to, but because you couldn’t afford it. Who gets the job? More troubling still, who decides that question is even worth asking?

This isn’t a thought experiment ripped from science fiction. It’s the genuinely uncomfortable trajectory of a neurotech industry that, according to market projections tracked across multiple analyst reports, is expected to grow from $2.84 billion in 2024 to $11.2 billion by 2035. The broader neurotechnology sector may balloon from $15 billion to well over $58 billion across that same window. Money is pouring in. Ethics are limping behind. And the questions about who benefits, who governs, and who gets left holding nothing but a headache are getting louder.

To be fair, this field started in the right place. Brain-computer interfaces were originally conceived as tools for people who desperately needed them: patients with ALS, paralysis, locked-in syndrome, Parkinson’s disease. Blackrock Neurotech has enabled BCI users to type at up to 90 characters per minute using thought alone. Synchron’s endovascular device lets paralyzed patients send emails and control devices without a single hole drilled in the skull. These are real, meaningful breakthroughs for people with limited alternatives.

But the neurotech story does not end there. It never does. Elon Musk has stated openly that Neuralink’s long-term goal isn’t just treatment, it’s to “unlock human potential” in healthy people. And once that door opens even slightly, the ethical architecture gets a lot more complicated.

The rise of the neuroelite

There’s a term circulating in bioethics circles that deserves more airtime: “neuroelite.” It was used pointedly at a UNESCO Futures Dialogue in late 2025 to describe a class of wealthy individuals who might use neurotechnology not to treat illness, but to gain cognitive advantages unavailable to everyone else. One panelist called it “the Botox of the brain.” It’s a sharp analogy. And like Botox, it exposes something uncomfortable: when a technology is positioned as enhancement rather than treatment, it transforms from a medical tool into a consumer product. And consumer products have never been free. 🧠

The concern isn’t hypothetical. UNESCO’s own analysis of neurotechnology ethics explicitly warns that limiting advanced neurotech to the wealthy could widen existing social gaps and, in their words, “lead to social tensions and conflict.” Researchers publishing in the Balkan Medical Union journal in 2025 echoed the same worry, noting that unequal access to BCIs risks entrenching new forms of social division rather than erasing old ones.

What makes this particularly sharp is the speed of the gap’s potential widening:

• An invasive neural implant currently requires surgery, neurological expertise, and ongoing clinical maintenance

• Consumer-grade EEG headsets cost anywhere from a few hundred to several thousand dollars

• The most capable devices, like Neuralink’s N1 chip, sit behind clinical trial walls with no public pricing

• Wealthier nations are already ahead: the U.S. has over half of the world’s BCI recipients, per MIT Technology Review data 🔬

Think about your own reaction here: does the idea of a cognitive upper class strike you as distant and unlikely, or closer than comfortable? Share your honest answer in the comments, because how a community frames that question shapes what it demands from regulators.

The race dynamic makes this worse. China has formally designated brain-computer interfaces as one of seven strategic innovation areas, with multiple government ministries backing a five-year roadmap toward global BCI dominance by 2030. The U.S. response, largely private-sector-driven, has no equivalent coordinated equity mandate. A technology race between nations prioritizing strategic advantage rarely produces equitable distribution. 🌍

Your thoughts, their data

Set aside surgery for a moment. The subtler, more immediately urgent version of this problem is already in your living room.

Emotiv sells EEG earbuds for everyday use. Neurable ships headphones that monitor your cognitive load. Apple’s Vision Pro reportedly uses AI to infer emotional and attentional states from users’ biometric signals, according to former Apple Neurotechnology Prototyping Researcher Sterling Crispin. These are non-invasive, accessible, consumer-facing products, and they generate neural data at scale, right now.

Here is what makes that genuinely alarming rather than merely interesting: most existing privacy law was not built for this. Your credit card data, your location history, your browsing behavior are covered by a patchwork of regulations. But the electrochemical signature of your mental state? Until very recently, largely unaddressed. ⚡

That’s finally beginning to shift. A 2024 survey conducted across the U.S. found that the majority of Americans consider brain data at least as sensitive as genetic or financial data, and many are worried about corporate misuse. Courts and legislatures are starting to catch up:

• California’s SB 1223 (signed September 2024) classifies neural data as “sensitive personal information” under the California Consumer Privacy Act

• Minnesota went further, signing a law in May 2024 under Governor Tim Walz that includes criminal penalties for violations of neural data rights

• Chile amended its constitution to protect “mental integrity” and ordered the deletion of brain data collected from a former senator

• Brazil’s Rio Grande do Sul has enacted similar protections, and Mexico is advancing a constitutional amendment

These are meaningful steps. But they’re patchy, they’re territorial, and neurotech companies building products for global markets routinely exploit the gaps. MedCity News reported in December 2025 that neurotechnology “must be designed from the outset with audit trails, clear safety limits, and accountability,” calling out the failure to treat neural data governance the way it should be: exceptional, not merely routine. 🔐

Duke Law professor Nita Farahany, whose book The Battle for Your Brain has become essential reading in neuroethics, frames this as a right to cognitive liberty, the fundamental claim that individuals should control their own mental processes without surveillance or manipulation. She’s argued that cognitive liberty is a non-zero-sum right, meaning that protecting one person’s mental autonomy doesn’t subtract from anyone else’s. The problem is that without enforceable legal teeth, it stays a philosophical concept rather than a protection.

Regulations are running to catch up

In September 2025, Senators Chuck Schumer, Maria Cantwell, and Ed Markey announced the MIND Act, the Management of Individuals’ Neural Data Act. According to analysis from CSIS, it marks Congress’s first serious attempt to regulate the neurotech industry as neural data shifts from medical settings into consumer markets. The bill defines neural data as any information obtained by measuring activity of an individual’s central or peripheral nervous system, and frames cognitive biometric data as particularly sensitive because it can reveal mental states and emotions. 📋

That framing is exactly right. But legislation alone isn’t sufficient, for a few reasons that are worth naming clearly:

• Regulation moves at policy speed; neurotech moves at VC speed. In 2025 alone, disclosed neurotech funding surpassed $1.3 billion, a figure tracked by NeurotechMag’s analysis of the sector’s tipping point signals

• Regulatory frameworks distinguish poorly between therapeutic BCIs (helping the paralyzed walk or speak) and augmentative BCIs (making healthy brains faster). That distinction matters enormously for equity

• The OECD’s Recommendation on Responsible Innovation in Neurotechnology, adopted by 39 countries, outlines nine principles but lacks binding enforcement mechanisms

• Most regulatory bodies lack the neuroscience expertise to evaluate what they’re being asked to approve

The MIND Act, if passed in something close to its proposed form, would be a start. But history suggests that the gap between “start” and “sufficient” in technology regulation is very wide indeed. Social media had years of regulatory runway before meaningful oversight arrived, and the damage done in that interval was enormous. As MedCity News put it, the lesson is clear: neurotech should not repeat the mistakes of social media. 💡

A related problem researchers from PMC flagged in a 2025 paper is that existing oversight bodies, including Institutional Review Boards, were built to assess clinical research, not consumer or workplace applications of BCIs. The IEEE Neuroethics Framework offers more structured guidance, including evaluating ethical, legal, and sociocultural implications across use cases. But it’s voluntary, and voluntary frameworks in commercially lucrative spaces tend to get observed selectively.

What equitable access would actually require

Here’s where I think the discourse gets muddled. The equity conversation in neurotech often defaults to “we need more regulation,” which is true but incomplete. It also needs to include:

First, clinical trial diversity. If you look at who has received brain implants so far, roughly 75% of BCI recipients have been male, and more than half are in the United States. This matters because BCIs tuned primarily on one demographic’s neural data may not work as well on others. That’s not an abstract justice concern; it’s a concrete efficacy problem.

Second, a clinical-first sequencing rule. Several neuroethicists, including researchers publishing in Frontiers in Human Dynamics in 2025, have argued that augmentative BCIs should not be commercially available until therapeutic applications have proved effective, safe, and accessible across income levels. You shouldn’t be able to buy a cognition boost for $10,000 while people with ALS still can’t reliably access a communication implant. The sequencing matters. 🧬

Third, open-source and DIY neurotech as a legitimate access pathway. IEEE Spectrum has covered the emergence of DIY EEG platforms like PiEEG, available for around $250, that put BCI development within reach of researchers who aren’t backed by venture capital. Open-source hardware won’t deliver Neuralink-level performance, but it could lower the floor of access significantly. Treating open-source neurotech as a serious part of the equity solution rather than a hobbyist curiosity is a reframe worth making. 🔓

Fourth, children and adolescents need specific protections. UNESCO’s dialogue noted that children’s brains are not yet fully developed, which makes them more vulnerable to cognitive manipulation and neural data misuse, not less. Current frameworks largely address adult consumers. This is a gap that is not theoretical; it’s already relevant given the number of EEG-based attention tools marketed toward schools.

And fifth, international governance needs actual teeth. Chile’s constitutional amendment produced a court order to delete brain data. That’s accountability in action. The OECD’s soft-law approach hasn’t produced equivalent results anywhere. The Neurorights Foundation, led by Columbia neuroscientist Rafael Yuste, has been pushing hard for neurorights to be recognized in national constitutions globally, which would anchor them in a way that regulatory guidance simply cannot.

The question at the center of this

None of this is resolvable by any one actor. Not Neuralink, not the FDA, not UNESCO, not the MIND Act. What would actually change the trajectory is a sustained, public insistence that brain enhancement technology must be treated as a public good with access obligations, not a luxury product with charitable exceptions.

The comparison to vaccines is instructive. Society eventually decided that certain medical technologies were too consequential to distribute purely on market terms, and we built infrastructure to reflect that. The decision came slowly, imperfectly, and only after a lot of preventable harm. Whether neurotech takes the same slow path or a faster one depends significantly on how loudly and specifically the people who understand this field demand better.

Here’s the question I’d leave you with: If cognitive enhancement became widely available and genuinely effective in the next decade, would you want access regulated as a right or priced as a product? And do you think the industry, as it’s currently structured, would get to the answer you prefer on its own? 🧠

The stakes aren’t small. They’re the architecture of what human potential means, and who gets to develop it.

Anxiety keeps millions stuck in a loop of worry while therapy waitlists stretch for months and pills bring their own baggage. New brain devices change that equation. They read your brain activity or send gentle currents to key areas so you dial down the stress response yourself. These tools hit the market fast in 2025 and 2026, and early users report calmer days without appointments or prescriptions. I think they work best as partners to lifestyle changes rather than magic fixes, yet the convenience stands out.

Neurofeedback and stimulation target anxiety at the source

Neurofeedback devices pick up EEG signals from your scalp and give instant audio or visual cues when your brain shifts toward calm patterns. tDCS headsets deliver low-level current to tweak activity in mood-related regions like the prefrontal cortex. Both avoid drugs completely. 🧠 ⚡ 🧬 The idea sounds high-tech, but the experience feels simple. You wear a comfortable band, open an app, and follow guided sessions that reward relaxed brain states.

Alpha-Stim clips to your earlobes for quick sessions. Flow Neuroscience and Roga Life use targeted stimulation to cut cortisol and ease rumination. Recent studies back their approaches for stress reduction.

• EEG headbands like Muse show your brainwaves live so you learn to produce more alpha waves

• tDCS devices such as Flow Neuroscience FL-100 gently boost activity in areas linked to mood regulation

• CES options like Alpha-Stim deliver mild currents through ear clips

• Home sessions last 20 to 40 minutes and fit into lunch breaks or evenings

• Data tracking builds patterns over weeks to show progress

What does your own anxiety pattern look like on a typical day? These gadgets make that visible for the first time.

Leading devices you can actually use today

Muse S remains popular because the fabric headband feels good for longer sessions and the app turns meditation into a game with soundscapes that respond to your focus. Flow Neuroscience gained FDA approval for its FL-100 tDCS headset in December 2025, making prescription at-home treatment available for mood issues including anxiety overlap. Roga Life sits behind the ears like headphones and stimulates nerves to halve stress symptoms in some users. 💡 📈 🔬

Myndlift and Mendi offer more affordable neurofeedback entry points for people who want to train attention and calm together.

• Muse S excels at guided meditation with real-time brainwave scoring

• Flow FL-100 brings clinical-grade tDCS into living rooms under doctor supervision

• Roga Life targets stress directly with portable nerve stimulation

• Myndlift pairs with clinician guidance for personalized anxiety protocols

• Mendi uses fNIRS and EEG feedback for accessible home training

Check 7 surprising ways brain-computer interfaces already appear in daily life for more everyday examples. I like how these avoid the waitlist problem entirely.

Evidence and limitations shape realistic expectations

Clinical results look promising but stay mixed. Muse users often report lower anxiety scores after consistent use. Flow’s trials showed strong remission rates for depression, with anxiety benefits following similar paths. Roga’s research indicates measurable drops in worry. Still, individual responses vary by how well the device fits your head and how regularly you use it. 💊 🧬

No device replaces professional care for severe cases. They shine as bridges or daily tools when therapy access lags.

• Consistent daily use over four to eight weeks usually shows the biggest shifts

• App integration keeps sessions engaging with progress graphs

• Side effects stay mild, mostly skin irritation or mild headaches at first

• Cost range runs from a few hundred dollars to prescription models

• Insurance pathways start opening for some approved devices in 2026

Read more on 6 signals that neurotech is reaching a tipping point to see where the field heads next. Privacy matters here because your brain data reveals sensitive patterns.

Choosing the right device and getting started

Match the tech to your lifestyle. Busy people like the quick ear-worn Roga option, while meditation fans pick full headbands. Start small and track how you feel after two weeks. 🌱 💡

For the science basics, see the neurofeedback page on Wikipedia. Visit the transcranial direct current stimulation overview and Flow Neuroscience for the latest on their tDCS approval.

• Budget buyers begin with entry-level EEG bands under $400

• Clinically focused users pursue prescription tDCS with doctor oversight

• Tech enthusiasts experiment with open platforms for custom protocols

• Stress-first routines favor quick nerve stimulators for on-demand relief

The FDA moves in late 2025 signal faster access ahead. These devices do not fix everything, but they give people tools to manage anxiety on their own schedule.

Would you try a brain device for anxiety relief if it meant skipping the waitlist and side effects?

Consumer neurotech no longer lives in labs or hospitals. You can buy an EEG headband today, pair it with your phone, and get instant feedback on whether your brain stays locked in or starts to drift. CES 2026 brought brain-tracking gaming headsets and FDA-cleared in-ear sensors that push the tech further into everyday use. I think a few options already beat old-school productivity hacks for certain tasks, yet plenty still feel like expensive toys. This guide cuts through the noise so you decide if any device deserves space on your nightstand or desk.

What consumer neurotech actually delivers right now

These gadgets read electrical signals from your scalp or ear canal and turn them into simple scores or audio cues. Non-invasive EEG sensors sit inside soft bands or earbuds so you avoid surgery. The best ones pair with apps that coach you in real time, like gently chiming when your attention wanders during work. 🧠

Neurable teamed with HyperX to embed sensors in gaming headphones that track focus during long sessions. Results from early testers show quicker recovery from distractions. The market for wearable neurotech hits $2.61 billion this year, according to recent industry numbers, because people want data on their brains the same way they track steps.

• Focus tracking flags when your mind drifts so you snap back faster

• Sleep optimization plays sounds timed to your brainwaves to shorten the time it takes to fall asleep

• Meditation scoring rates session depth and suggests breathing adjustments

• Cognitive readiness from in-ear devices like IDUN Guardian 4 tells you if your brain feels sharp before a meeting

• Hands-free alerts appear in new earbuds that detect micro-gestures linked to thought patterns

If you already use a fitness tracker, adding brain data feels natural. Think about the last time your focus slipped during a deep task. Would a gentle nudge from your own brainwaves help?

Devices that earn their price tag in 2026

Muse S Gen 2 remains a favorite for meditation fans because its fabric band feels comfortable for nightly use and the app delivers clear sleep insights. Emotiv Insight appeals to tinkerers who want five channels of raw data for custom experiments. The Neurable x HyperX gaming headset prototype earned multiple CES 2026 awards for turning playtime into performance training. 🛠️

IDUN Guardian 4 earbuds give a cognitive readiness score without a bulky headband, which makes them easy to wear all day. NAOX LINK just cleared the FDA for in-ear EEG monitoring, so clinical-grade tracking now fits in your pocket.

• Muse S Gen 2 costs around $500 and shines for sleep and calm routines

• Emotiv Insight runs about $499 and works for hobbyist brain-computer interface projects

• Neurable x HyperX prototype targets gamers who lose focus mid-match

• IDUN Guardian 4 earbuds deliver subtle feedback during meetings or workouts

• NAOX LINK offers FDA-cleared accuracy for everyday brain monitoring

Read more practical examples in 6 Brain-Computer Interface Products You Can Use Today. I find these standouts because they solve one clear problem instead of promising everything at once.

Match the tech to your actual goals before you buy

Not every device fits every person. Start by listing your biggest mental hurdle, then shop accordingly. 🧬 High-performers chasing flow states lean toward gaming headsets, while parents fighting bedtime chaos pick sleep-focused bands.

The field grows fast, with companies racing to add AI that predicts your next distraction. Still, accuracy varies by hair type, sweat levels, and how well the sensors touch skin.

• Busy professionals pick in-ear options for all-day wear without looking odd

• Meditation regulars grab soft headbands that double as sleep aids

• Gamers and coders test brain-tracking headphones that flag tilt before it hits

• Students use affordable five-channel sets for study-session feedback

• Early adopters experiment with open platforms like Neurosity Crown for custom apps

Have you ever wondered why some mornings feel productive and others drag? These tools can reveal patterns your calendar misses. For deeper context on how brain interfaces already sneak into daily life, check 7 Surprising Ways Brain-Computer Interfaces Are Already in Your Life.

Real risks and smart ways to handle them

Privacy tops my list of concerns because your brainwave data reveals more than a smartwatch ever could. Companies store patterns that could one day show mood or even thoughts if regulations lag. Cost also stings: most solid options run $300 to $500, and you still need the app subscription for full features. Signal quality drops if you move around a lot, so results feel inconsistent at first.

Data ownership stays murky even with new UNESCO guidelines from late 2025. I worry that early buyers become unwitting beta testers while the tech matures.

• Privacy policies vary, so read them before syncing your phone

• Fit and comfort matter more than channel count for daily use

• Return windows let you test at home for two to four weeks

• Battery life limits all-day wear on some models

• App ecosystems determine how useful the raw data becomes

Learn about broader neurotech edges in 7 Competitive Advantages Only NeuroTech Companies Can Build. For the basics of how these signals work, see the brain-computer interface overview. The Neurable and HyperX partnership gives a clear look at where gaming meets brain tech, detailed in this CES 2026 announcement.

So here is my question for you: what single mental habit would you upgrade first if a $400 device actually delivered consistent results?